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APOBEC1-MEDIATED RNA EDITING IN MONOCYTES CONTRIBUTES TO
GENETIC HETEROGENEITY AND MODULATES MONOCYTE ACTIVITY AND
DEVELOPMENT

Violeta Rayón Estrada, Ph.D.
The Rockefeller University 2017

Post-transcriptional modifications such as alternative splicing have been shown to
add to the complexity needed to compensate for the relatively low number of genes found
in higher organisms. Many other modifications recently found in mRNA, which cannot
be deduced from what is coded in the genome, such a cytidine to uridine and adenosine to
inosine editing, reveal that this complexity is ever expanding. Therefore, the current
challenge is to understand what is the function of these modifications. In this thesis, I
focus on APOBEC1-mediated RNA editing.
In higher eukaryotes RNA editing consists of C to U and A to I transitions
mediated by the proteins of the APOBEC1 and ADAR families, respectively. APOBEC1
has been fully characterized in its role of editing the Apolipoprotein B (ApoB) transcript
in the intestine, where the C to U modification changes a glutamate codon to a stop
codon, creating a smaller version of the ApoB protein. Editing of ApoB is essential for
the formation of the chylomicron, a lipid transport protein, making APOBEC1 a crucial
enzyme for lipid metabolism.

In recent years, our laboratory developed a comparative approach that uses an
Apobec1-deficient mouse in order to find true Apobec1-mediated editing events in
wildtype mRNA. This method allowed for the discovery of additional sites in a
transcriptome-wide manner. Using this, we were able to identify hundreds of additional
edited sites in murine intestine and macrophages. This opens up the possibility of
alternative APOBEC1 functions. In this thesis, I focus on the edited sites within
macrophages, where Apolipoprotein B is not expressed and therefore, where APOBEC1
may play an alternative role to lipid metabolism. Specifically, these consist of 410 highconfidence C to U editing events contained in 275 transcripts, the large majority of which
are within the 3'UTR.
First, finding that there are no transcriptional differences between macrophages
derived from Apobec1-deficient and wildtype mice, I characterized the fate of these
transcripts at the molecular level. Previously, ADAR editing has been shown to
potentially regulate transcript abundance by nuclear retention and stabilization. Here I
demonstrated that this is not the case for APOBEC1. However, even though at the RNA
level, there seem to be no alterations due to editing, I showed that editing does regulate
translation of protein products, some of which are miRNA mediated.
The changes observed at the protein level are nevertheless quite small, which is to
be expected from the low frequency of editing per transcript. However, a very longstanding question in the field is whether this is the reflection of a few cells within the
population that possess 100% editing per site or whether each cell has low frequency
editing. In order to test for this, we created a statistical model that tested the variability of
editing at each site among many cells of the same population. Using this model, we

observed that cells are indeed quite variable in terms of editing. Then I validated the
results of the model using barcodes that identify individual RNA molecules to amplify a
region surrounding the edited sites in single cells. Altogether, these experiments
demonstrated that within the population, cells that are seemingly transcriptionally
identical are indeed heterogeneous.
Next, I tested whether the loss of this variability might affect the activity of
macrophages. To do this, I designed in vitro and in vivo assays. I demonstrated that
Apobec1-deficient macrophages have altered migration and phagocytosis phenotypes in
vitro. This predicts that the physiology of monocytes in the Apobec1-deficient mouse
would be altered. While setting up a competitive reconstitution in vivo assay, where I
would be able to test wildtype and Apobec1-deficient monocytes side by side, I
discovered that the development of monocytes is not equivalent between the two
genotypes. Surprisingly, Apobec1-deficient monocytic progenitors tend to outcompete
their wildtype counterparts and monocytes have an increased preference to form a proinflammatory Ly6C positive phenotype. Finally, I present a possible link between loss of
Apobec1 and brain disorders.
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CHAPTER 1. INTRODUCTION

The processing of messenger RNA leads to the diversification of the genes in the
genome by creating alternative proteins though processes such as alternative splicing,
alternative initiation and termination, frame shifts etc. However, all of these
modifications are variations of what is encoded in the genome. In this chapter I will
survey other types of post-transcriptional processing that cannot be deduced from what is
coded in the genome. Then I will focus on RNA editing, which is a process that directly
recodes the message through adenosine to inosine and cytidine to uracil nucleoside
transitions. I will show that these types of modifications have been demonstrated to have
big biological implications. Finally, I will survey of the state of apolipoprotein B mRNA
editing catalytic polypeptide 1 (APOBEC1) research at the moment I began my studies
and will present some preliminary studies performed in my laboratory.

1.1. Post-transcriptional modifications
The post-transcriptional modification of RNA is a naturally occurring process that
occurs during the maturation of RNAs. Today, more than 100 distinct ribonucleoside
modifications are known and have been shown to be present in all three phylogenetic
domains: archaea, bacteria and eukarya1. These modifications are most abundant in noncoding RNA (ncRNA), where they are crucial for properly aiding in translation and
splicing1.
Transfer RNA (tRNA) modification is a good example where modifications play
a very important role in its structure and function. tRNA is both the most highly modified
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(with 25% of its nucleosides altered) and the one with the most complex chemical
variety1. For example, different combinations of modifications provide plasticity so that
tRNA can adopt subtle features like increased rigidity or flexibility2. Rigidity can be
enhanced for example, by the presence of ubiquitous pseudouridines partly by
coordinating stabilizing water molecules3. On the other hand dihydrouridine provides
flexibility4. Maintenance of the optimal tRNA structure however, seems to require both
modifications, suggesting that coordination of a network of modifications is needed for
proper stability5.
Modification of mRNA with N6-mathyladenosine (m6A), 5-methylcytidine (m5C)
and ribose methylations have been known for decades6–8. Besides these, four additional
base modifications have been discovered so far in mRNA: inosine (I), pseudouridine (Ψ),
5-hydroxymethylcytidine (hm5C) and N1-methyladenosine (m1A)9. A few of these
modifications have been well characterized, for example inosine, pseudouridine and m6A
have been shown to influence the metabolism, function1, localization, or stability of
transcripts to rapidly adjust the transcriptome in response to developmental and
environmental cues10–12. Moreover m6A is found in the 5’ untranslated region and marks
the beginning of transcripts in mRNA13. It is now clear that all these modifications in
mRNA are not passive marks. However, research in this area is still emerging, and new
techniques that incorporate high throughput RNA sequencing are allowing for the
identification of hundred of additional marks in mRNA. Therefore little is known about
their role and which are the writers (enzymes that put the marks on) and readers of these
emerging marks.
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1.2. RNA editing
The term RNA editing was originally coined to describe the insertion of 4
uridines in the coding region of the mitochondrial cytochrome oxidase subunit II gene in
Trypanosoma brucei, which restores the frame shift encoded in the DNA14. This
nucleotide insertion, which cannot be deduced from genomic sequence, allows for the
formation of a functional protein, essential for generating functional mitochondrial
proteins in trypanosomes15. The discovery of other changes in the sequence of transcripts
led to the re-definition of RNA editing to include all type of modifications that result in
sequence changes in the RNA from what is encoded in the genome. These modifications
now include insertion, deletion and modification of nucleotides16.
Modification of nucleotides is performed by the cytidine deaminase (CDA)
superfamily of enzymes that includes both the adenosine deaminases acting on RNA
(ADAR) and the apolipoprotein B mRNA editing catalytic polypeptide 1 (APOBEC1)
family of proteins, as well as the adenosine deaminase acting on the tRNA (ADAT)
family17. In higher eukaryotes, base modifications are the major type of RNA editing18.
RNA editing is restricted to base modifications of two types: cytidines to uridines (C to
U) and adenosines to inosines (A to I). These modifications are the result of enzymatic
deamination catalyzed by enzymes of the APOBEC1 and ADAR families, respectively
(Figure 1.1).
RNA editing, as well as other RNA post-transcriptional modifications like
alternative splicing, serves to diversify the genome, expanding the limited number of
genes given the complexity of higher organisms. Using RNA modification strategies,
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Figure 1.1 | Deamination by the ADAR and APOBEC1 families.
Deamination of adenosine to inosine (A to I) in an RNA polynucleotide is
catalyzed by the ADAR family of adenosine deaminases (top). APOBEC1 family
members catalyze the deamination of cytidine to uridine (C to U; bottom).
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many different gene products can be created that fill in the requirements of complex
structural, enzymatic and regulatory functions.

1.2.1. Adenosine deaminases
The ADAR family of CDAs posses a conserved modular domain constitution
consisting of a variable N-terminal domain, one to three repeats of a double stranded
RNA-binding domain (dsRBD) and a catalytic deaminase domain in the c terminal19. The
catalytic domain consists of amino acid residues conserved with cytidine deaminases,
including Apobec120. Mammals have 3 ADAR proteins21, which are highly conserved in
vertebrates. In contrast, lower metazoan organisms such as Caenorhabditis elegans22 and
Drosophila melanogaster23 only posses one and in a few organisms, like protozoa, yeast
and plants, ADARs are absent24. ADAR1 and ADAR2 arose early in metazoan evolution,
proven by their presence in in sea urchin and sea anemones24. ADAR3 probably arose
later in evolution, as a duplication of ADAR2 in vertebrates. Interestingly, ADAR was
lost in some species such as insects and squid during subsequent evolution24.
ADAR1 and 2 have confirmed enzymatic ability to convert A to I in double stranded
RNA substrates20,25–27 and are present in many cell types, with highest amounts in the
brain28. ADAR3 is brain specific and can bind to single as well as double stranded RNA,
but it is thought to be catalytically inactive27. The editing activity of ADARs requires
homodimerization, being that ADAR3 can bind to ADAR 1 and 2, it is thought to act as
an inhibitor27. ADARs have a diverse set of substrates: ADAR 1 and 2 will edit almost
any double stranded structure, made up of inter- or intra-molecular interactions that make
at least 2 helical turns (~20nt)29. ADARs are also quite promiscuous, with adenosines
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contained in long stretches of dsRNA edited ~50%. In contrast to this, short dsRNAs or
long RNAs with imperfect mismatches (loops, bulges, etc.) are edited selectively,
indicating that the selectivity is dictated by the secondary structure of the dsRNA30. In
addition to the double stranded structure, selective editing requires a downstream
complementary sequence (ECS) that is crucial for exonic editing, for example in editing
of the Ampa receptor subunit GluR-B31.

1.2.2. Role of ADARs in development and protein diversification
ADAR 1 and 2 are expressed in many tissues, whereas ADAR3 is only expressed
in the brain20,25–27. In mouse development, ADAR 1 and 2 expressions start at around E10
in the heart. Both ADAR1 and its regulator miR-1 are important for the embryonic heart
development32. Models that contain deletions in ADAR genes give an insight into the
importance of ADAR in development. ADAR1 deficient mice die quickly in utero due to
generalized apoptosis32,33. Conditional activation studies of ADAR 1 also demonstrated
that it is important for the maintenance of the hematopoietic stem cell33.

ADAR2

deficient mice die soon after birth due to neurological deficiencies resulting from deregulated GluR34. These mice can be rescued with genomic editing of the receptor34.
Originally, ADAR editing was thought to be restricted to ~30 transcripts, within
coding regions. Most of these transcripts are ion channels and neurotransmitters, for
example GluR31, the serotonin 2c-receptor G-protein subtype 5-HT2CR35 and the
potassium channel Kv1.1A36. In these cases the recoding results in the generation of
protein isoforms and the diversification of their functions. A mutation of a glutamine
(CAG) to an arginine (CIG) in the GluR receptor at a site known as the Q/R site changes
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the proteins tertiary structure such that the whole channel becomes impermeable31,37 to
Ca2+. But the complexity does not end there. The glutamate receptor unit GluR-6 harbors
3 exonic editing sites (known as I/V, Y/C and Q/R) that all together give rise to 8
different sequence combinations. Because the extent of editing at each site varies
between 10 and 80%, all possible theoretical combinations of the protein products can be
found in the nervous system38. Just as complex is editing of five sites within 3 codons of
the 5-HT2CR (isoleucine AUA, asparagine AAU and isoleucine AUU), which results in
up to 6 amino acid changes and in combination, 24 receptor isoforms with variable
potency and ligand binding35,39. Finally, 14 edited sites identified in the potassium
channel Kv1.1 lead to many kinds of outcomes such as inhibition of tetramerization and
changes in the rate of deactivation40.
Editing has been implicated in certain diseases of the brain. For example,
underediting of the Q/R site of the GluR has been observed in the death of motor neurons
of sporadic amyotrophic lateral sclerosis (ALS) patients41. Also, the editing pattern of 5HT2CR mRNA is significantly altered in the prefrontal cortex of suicide victims42 .

1.2.3. Functional roles of ADAR editing
The protein coding ADAR-mediated modifications mentioned above are just a
small fraction of the transcripts targeted by ADAR. Using new bioinformatic approaches,
a wide number of sites have been discovered, mostly within inversely oriented repetitive
elements in non-coding regions, especially within Alu regions (short interspersed
elements that are unique to primates) and Long interspersed nuclear elements (LINE)43,44.
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Editing of non-coding regions involves ADAR into to several processes:
alternative splicing, nuclear retention and interaction with miRNA pathways. Alternative
splicing can come about when ADAR targets 2 nucleotides to create a novel splice site:
the highly conserved canonical 5’ GU (from AU) recognition sequence or the 3’ splice
acceptor AG (form AA) site43. In the same way, it can destroy the 3’ splice site AG (from
GG)44.
Nuclear retention has been identified for the mouse cationic amino acid
transporter 2 (CAT2). The mechanism is believed to involve A to I editing on SINE
elements present within its 3’UTR, which mediate binding to the nuclear retention
protein p54ntb. This interaction traps the RNA of CAT2 in nuclear speckles known as
interchromatin granule clusters45.
It has been shown that ADARS modulate different pathways of miRNA synthesis,
leading to suppression or enhancement of miRNA processing steps. In hematopoietic
cells for example, ADAR1 and 2 edit pri-miRNA-142, which results in degraded by the
nuclease Tudor-SN46. Another example is the processing of pri-miRNA-151, which is
also a substrate of both ADAR1 and 2. Editing of this pri-miRNA inhibits its cleavage by
Dicer and its accumulation suppresses the expression of mature miRNA-15146.
ADAR editing can also antagonize miRNA-mediated gene silencing, through
interference with the miRNA-induced silencing complex (miRISC) assembly. One
example where this occurs with the Epstein Barr virus encoded pri-miRNA BART6.
Upon editing of this pri-miRNA the loading efficiency of miR-BART6 to the miRISC
reduces, lowering the silencing of it’s target mRNA47. Additionally, mature miRNAs
have been found to be edited and are predicted to repress a set of genes that differ from
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those targeted by the unedited miRNAs. This is the case for miRNA-376, whose seed
sequence is edited by ADAR2 in the +4site, essential for its binding to the
complementary sequence in mRNA48.
Finally, a role for miRNA regulation has been proposed for ADAR 1 and 2,
independently from their RNA editing role. A catalytically inactive ADAR2 has been
shown to inhibit Drosha processing of pri-miRNA-376a2 through RNA binding.
Furthermore, there is evidence that ADAR1 can form a heterodimer complex with Dicer
to promote cleavage of miRNAs and facilitates loading of miRNA into other silencing
complexes49.

1.2.4 ADARs in the innate immune response
In its role as an adenosine deaminase, ADAR participates in the response to viral
infection, for example in brain infections with the measles virus, samples form patient
brains show that 2% of the nucleotides were edited, resulting in alteration of reading
frames and fused genes50. This reaction has been characterized to involve the IFNinducible ADAR p150 isoform51. Another example is the hepatitis C virus (HCV)
sensitivity to interferon-α (IFNα). Many clinical HCV infections are resistant to IFN-α
therapy. However, subgenomic in vitro self-replicating HCV RNAs (HCV replicon) have
a marked IFNα sensitivity52. In this case IFNα increases the expression of ADAR1
resulting in a decrease of viral replication that leads to genomic instability.
ADAR can also establish a proviral response, depending on the type of virus. The
hepatitis delta virus (HDV) requires a larger version of its short DNA encoded HDV
antigen for packaging its genome into virions. In order to do so it takes advantage of
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ADAR1 editing to provide the change necessary for the formation of the larger HDV
antigen by changing a UAG stop codon to a UIG tryptophan codon53.
Another function of ADAR in the immune response is in the distinction of “self”
dsRNA from that generated through viral infections. Viral dsRNA comes from many
sources including dsRNA genomes, hairpin secondary structures in mRNA and
replication of ssRNA viruses. If the dsRNA is found in the cytoplasm, it will encounter
the retinoic acid-inducible gene I (RIG-I) and melanoma differentiation-associated gene 5
(MDA5) receptors, which will induce a type I IFN response, unless dsRNA possesses
inosine in its structure54. In this scenario, ADAR1 is a negative regulator of the type I IFN
response by editing viral dsRNA, which is then confused as “self”, through specific
binding to RIG-I and MDA555. The elucidation of this process was pieced together
though studies of ADAR deletion. First, mouse embryonic fibroblasts deficient in
ADAR1 p150 are highly susceptible to infection and have enhanced viral induces
cytotoxic effects51. This study implicated ADAR1 in the repression of type I IFN
response. Also, in the search for the mechanism by which ADAR1 deletion causes
embryonic lethality, the generation of a double mutant Adar1+/- and Mavs-/- led to the
discovery that embryos that were homozygotes for both survived to birth54. The surviving
embryos had a much less heightened IFN response, placing ADAR1 upstream of RIG-I
and MDA5 in the IFN activation pathway54.

1.2.4. Cytidine deaminases
The AID/Apobec family of cytidine deaminases consists of several members that
catalyze cytidine deamination in both DNA and RNA. APOBEC1 was the first member
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of its family to be discovered and thus bears the name of its first discovered substrate
Apolipoprotein B. Other family members include AID (Activation-induced cytidine
deaminase), Apobec2, Apobec3 (A-H) and Apobec4. All of these share a conserved
catalytic domain, which is zinc dependent (reviewed in Smith 2009), which has a big
resemblance to the ancestral domain found in cytidine deaminases acting on free cytidine
(Conticello, 2005). However, the AID/Apobec family is a later evolutionary development
restricted to the vertebrate lineage. The first member is thought to have been AID, which
arose concurrently with the development of adaptive immunity in vertebrates (Conticello,
2005).
Throughout evolution, AID/Apobec enzymes evolved rapidly, displaying the
strongest signals of positive selection in the human genome, which is a pattern associated
with host defense (Sawyer, 2004). For example, Apobec3, has undergone a dramatic
expansion in primates into 8 subfamily members, in comparison to mouse, which
possesses only one. Indeed, most family members function in immunity: AID is crucial
for antibody diversification through somatic hypermutation and class switch
recombination; and Apobec3’s act on both endogenous and exogenous retroviral
genomes (reviewed in Hamilton et al., 2010).
Until recently, the only known member of the AID/APOBEC family to act on
RNA was Apobec1: AID is restricted to double stranded RNA, Apobec3’s to single
stranded DNA and Apobec2 and 4 have no identified substrates. However, recent studies
published during the course of my thesis work, have demonstrated that a member of the
Apobec3 subfamily, Apobec3A can also edit RNA substrates56 (REF: Sharma 2015). The
canonical role of Apobec3A is related to its DNA editing ability in the inhibition of the
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replication of the adeno-associated virus (AAV), a small single stranded DNA
parvovirus57. Sharma and colleagues showed that in human monocytes, Apobec3A is
capable of editing a large number of endogenous mRNA transcripts and that editing
increased under different physiological conditions such as hypoxia and interferon gamma
induced inflammation56.

1.2.5. APOBEC1 editing
Apobec1 has a well-characterized function in the intestine, where it targets
cytidine 6666 in the transcript of ApoB, changing a glutamine codon (CAA) to a
termination codon (UAA)58,59 (Figure 1.2). The resulting truncated protein (ApoB48) is
functionally different from its full-length counterpart.

This is very important for

lipoprotein assembly and transport because ApoB is a structural protein of VLDL
particles, whereas ApoB48 is crucial for the formation of chylomicrons. As expected, the
loss of APOBEC1 in mice results in elevated LDL levels and cholesterol60 and is
associated with susceptibility to atherosclerosis61.
Editing of ApoB is regulated in a tissue specific manner through restricted
expression of Apobec1. In adult human intestine, where Apobec1 is expressed, the
efficiency of editing is >90%, in contrast to the liver, where ApoB remains unedited (in
mice ApoB is highly edited in both liver and intestine). Furthermore, editing of the
specific cytidine within the ApoB transcript seems to be exquisitely regulated and is
correlated to Apobec1 expression levels. In order to achieve its specificity, APOBEC1
requires the interaction with a multi-protein editing complex. The principal component of
this complex is the RNA binding subunit Apobec-1 complementation factor (ACF),
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Figure 1.2 | APOBEC1 editing of the Apolipoprotein B transcript results in
the creation of a smaller protein. APOBEC1 mediated deamination of cytosine
to uridine changes a glutamate (CAA) to a stop codon (UAA), which results in
the creation of a truncated protein, ApoB48. This is an organ-speciLic
mechanism that allows for the creation of two different lipid particles, VLDL and
chylomicrons, composed of ApoB100 and ApoB48 respectively.
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which together with Apobec1 forms the minimal functional editing enzyme complex62,63.
In contrast to Apobec158, ACF is an essential gene and mice lacking it die in the preimplantation stage of development64. ACF binds the transcript of ApoB through
recognition of an 11 nucleotide mooring sequence surrounded by an AU rich
environment. ACF has also been shown to protect the ApoB transcript with a premature
stop codon from nonsense-mediated decay65.
Liver –specific overexpression of Apobec1 in mice revealed Apobec1 changes its
specificity of editing in ApoB, resulting in extensive editing at multiple cytidines
downstream of the canonical one, a phenomenon known as hyperediting66. It is presumed
that the reason for this loss of specificity is the altered stoichiometry of Apobec1 to ACF,
which was confirmed with forced over expression of Apobec1 in vitro66–68. However, this
is not the case when the ratio is altered via reduced ACF in Acf+/- mice, who exhibit
increased hepatic editing at the ApoB canonical site but not hyperediting69. This indicates
that there is still much to be investigated about the stoichiometry of the proteins involved
in the regulation of the editing complex.

1.2.6. Alternative APOBEC1 activities
Besides its RNA editing ability, Apobec1 has been shown to have two activities
which have been observed in vitro but that are yet to be confirmed in physiological
conditions: modification of transcript stability and DNA editing.
APOBEC1 has been shown to be an RNA binding protein, with specificity to AUrich sites, similar to the one found surrounding the ApoB mooring sequence. Specifically,
it has been shown to bind the 3’ untranslated region (UTR) of c-myc, TNF-α and IL-2

14

when fused to luciferase reporters and alter their stability70. Similarly, it has been shown
that APOBEC1 can confer stability to the cyclooxygenase-2 (COX-2) transcript, which
contains AU-rich elements that mediate its decay, through binding of its 3’UTR, when
cloned into a luciferase vector. Altogether, these observations suggest that Apobec1 may
have a role in transcript stability, unrelated to its editing ability.
When tested in a DNA mutation model, the mutation induced rifampicin-resistant
E. coli, Apobec1 was shown to be a strong DNA mutator, displaying comparable if not
better activity as its close relative AID71. This was also confirmed biochemically using in
vitro deamination assays with bacteria-purified Apobec1 and DNA substrates. These
assays revealed that Apobec1 possessed weak C to U deamination, which was restricted
to single-stranded DNA substrates72. However, there is thus far no evidence of
APOBEC1-induced mutations in the genome of naturally expressing Apobec1 cells.

1.2.7 APOBEC1 in cancer
The jury is out on whether APOBEC1 is involved in natural tumor formation.
Evidence from over-expression models of APOBEC1 has shown that, in its role as a
DNA editor, it is a potential oncogene. However, there is still very limited evidence that
links APOBEC1 editing to cancer originating from patient samples. Evidence from both
instances is presented below.
Until recently, the only other known target of APOBEC1 editing was the
neurofibromatosis type 1 RNA (NF1) tumor suppressor, shown to be edited in a subset of
the patients affected with peripheral nerve sheath tumors (PNSTs)73,74. These patients
have a particular alternatively spliced version of the Nf1 transcript, which includes exon
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24A74. Apobec1 changes an arginine (CGA) to a translational stop codon (UGA) through
binding to a mooring motif similar to the one in ApoB. The resulting truncated protein
lacks the GTPase-activating protein region that is responsible for tumor suppression73.
This finding represents the first time that Apobec1 was found to act outside of the
intestine and opened up the possibility that Apobec1 may have alternative targets and
therefore additional function. This shows that Apobec1 could be involved with cancer
formation.
A second line of evidence that APOBEC1 could be involved in cancer formation
comes from studies in over-expression mouse models. For example, APOBEC1 caused
hepatocellular carcinoma in mice with transgenic hepatic overexpression. Upon
examination of edited targets, hyperediting in a novel Apobec1 target 1(Nat1) was
identified75. Nat1 binds the initiation factor 4a (eIF4A), which inhibits both capdependent and cap-independent translation. The aberrant editing alters amino acids and
creates multiple stop codons, which in turn result in the reduction of the protein. This also
shows an oncogenic potential for APOBEC1, however this evidence does not come from
physiological levels of APOBEC1 expression.
Further links of APOBEC1 with oncogenesis come from studies of testicular
germ cell tumors (TGCTs)76 and adenocarcinoma of the small intestine in tumorsusceptible mouse models77. In the Apcmin/+ mouse model of small intestinal adenoma
formation, loss of APOBEC1 reduced tumor burden, increased apoptosis and reduced
proliferation77. However, the authors speculated that the mechanism is through the
stabilization of transcripts such as COX-2, given that adenomas from Apcmin/+Apobec-/mice had a marked reduction in Cox-2 mRNA. This could point to an editing-independent
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oncogenic mechanism, however a genome wide search of alternative APOBEC1 targets
was not pursued, and so the possibility remains that editing could be involved.
However, a study that searched for aberrant APOBEC1 editing in tumor
specimens of different types, including hepatocellular, bile duct, gastric, colorectal,
pancreatic and breast carcinomas, failed to confirm that APOBEC1 editing is involved in
tumor genesis of these cancers78. This is the result of either low levels of APOBEC1, such
as in colorectal and lung carcinoma; or because whether an active version APOBEC1 or
the required cofactors are absent from the tumor sample78.

1.2.8. High throughput RNA seq identification of APOBEC1 editing
After a several year hiatus, research on APOBEC1 re-emerged as new sequencing
technologies became available and enabled the identification of new targets. In this
section I will describe research in my laboratory that set the basis for the discovery of
hundreds of additional sites, as well as preliminary experiments in macrophages.
High throughput detection of RNA modifications relies on the traces that such
modifications leave behind in cDNA, as the reverse transcriptase is confronted with noncanonical substrates. For example, large modifications tend to lead to arrest the reverse
transcriptase and modifications on the Watson-Crick pairing will lead to misincorporation
of non-complementary dNTP. The former results in shorter cDNA or abortive sequences,
while in the latter case, the signature results in apparent mutations in the cDNA sequence.
For example inosine, which is the result of ADAR-mediated deamination of adenosine,
pairs with cytidine leading to the incorporation of dCTP instead of dTTP onto the cDNA.
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These mutations can be then identified bioinformatically, through the comparison of the
cDNA sequence to its corresponding DNA sequence.
In order to find alternative functions for APOBEC1, we need to uncover the
universe of sites that are edited. To do this, our laboratory developed a comparative
approach to identify high confidence APOBEC1-mediated edited sites in a genome-wide
manner. The method is based on the analysis of mRNA high throughput sequencing data
taking advantage of the editing signatures in cDNA, where C to U editing causes the
misincorporation of dATP instead of dGTP. The pipeline takes the aligned reads from the
genome and quantifies the number of C to T mismatches in comparison to the genome.
Then a series of filters is applied: mismatches that map to known single nucleotide
variants are discarded. Finally, the list of the mismatches in wildtype BMDMs is
compared to their Apobec1-/- counterparts. Bona fide editing sites are ones that occur
only in the wildtype sample and are absent in the Apobec1-/- sample.
This method was used to identify APOBEC1 mediated C to U editing in mouse
intestine. As a result, 36 additional sites were identified. Interestingly, the site at the
Apolipoprotein B transcript is the only site located at the 3'UTR; all additional sites were
found in the 3' untranslated region of transcripts.

1.3. Statement of purpose
It is a very exciting time to do research in the field of epitranscriptomics given
that, with the development of new tools, we are now able to map large numbers of
modifications in mRNA. We know that many of them are found in tRNA and rRNA and
are crucial for the cell. In a similar manner, it is possible that such modifications play
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crucial roles not only for transcript processing and fate, but also for the adaptability of
cells to changing environments.
One of the modifications that have been thus far overlooked is C to U editing.
This is mainly because until recently, it was believed to be restricted to one enzyme
(Apobec1), one substrate (ApoB) and one system (intestine). Our group uncovered a
bigger universe of transcripts affected by Apobec1 and its physiological activity in
immune cells. This opens up the possibility that C to U editing has a bigger role than
previously thought. It is becoming clear that C to U editing is a widely used mechanism
of genetic diversification that warrants further studies.
Alternative functions of Apobec1 still remain to be established. The methods our
group created to globally identify APOBEC1 edited sites allowed us to have a good
catalog of APOBEC1 targets and edited sites in macrophages. In this system, ApoB is not
expressed, which raises the possibility that Apobec1 editing has a novel role unrelated to
lipid metabolism. I set out to provide answers, even if partial, to the following questions:
What is the purpose of Apobec1 editing in macrophages? Does editing confer additional
transcript regulation? Does editing regulate the activity of macrophages?
With these questions as main motivation of my work, I focused on two main
objectives: (1) to examine the functional consequences of editing at a molecular and cell
level; and (2) to find out what, if any, is the role of APOBEC1 in tissues other than the
intestine and liver.
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CHAPTER 2. IDENTIFICATION OF HIGH CONFIDENCE EDITED SITES IN
BONE MARROW DERIVED MACROPHAGES

The editing detection method mentioned in section 1.2.8 (above) can be directly
applicable to any kind of cell that expresses APOBEC1 or other editing enzymes.
However, in an effort to improve the detection method, our group further developed a
new method of editing identification that allowed us to confidently call low frequency
edited sites. Our group then looked at other systems that expressed APOBEC1 in which
it's activity could be characterized. The cell selected was bone marrow derived
macrophages, which are cells of the immune system that express very high levels of
APOBEC1, are readily available through differentiation of bone marrow progenitors (see
methods) and do not express the canonical co-activator ACF nor its canonical target
ApoB. Recently, RBM47, an RNA binding protein, was discovered to be a cofactor
protein for Apobec1 editing of ApoB mRNA79. Rbm47 has homology with ACF and is
able to form the core editing enzyme complex. This cofactor is expressed in BMDMs and
is a good candidate for aiding Apobec1 editing in these cells, although this remains to be
investigated.
The new editing pipeline is also based on a comparative RNA-seq approach80.
Briefly, RNA from resting wildtype and Apobec1-/- BMDMs was extracted and mRNA
libraries were made and sequenced. Once the reads were permissively aligned to the
reference genome, each site was scanned and mismatches to the reference genome were
quantified. Each type of mismatch was then used to build vectors (C, T, A, G) for each
chromosomal coordinate, with a corresponding vector for the Apobec1-/- sample. In
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order to determine true edited sites, the angle between the two vectors is compared. A
larger angle is a true edited coordinate (Figure 2.1). The method also incorporates filters
for artifacts: blat filter that eliminates reads mapping to alternative genomic sites; filters
for known variants, strand bias and variants at the end of reads, where a higher rate of
sequencing errors reside.
Using this method, we were able to detect 410 high-confidence C to U editing
events in 275 transcripts. The large majority of them (97%) were contained in the 3'UTR
of the transcripts and most of the sites were edited at low frequency 10-20% (Figure 2.2).
We also observed that the sites could be classified into single edited and hyperedited
(high frequency editing in one location, with additional lower frequency editing in
alternative nearby sites, figure 2.3.B). A great number of sites were validated by Sanger
sequencing of bacterial colonies containing fragments amplified from cDNA from
wildtype and Apobec1-/- BMDMs (Figure 2.3).
However, we found that the global gene expression of the genes between the two
genotypes is highly correlated (not shown), indicating that there are no differences in
gene expression between the two.
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Figure 2.1 | Pipeline for editing detection. (A) Depiction of vectors in a 4D
space, built for every substitution at every base in both genotypes using data from
the pileup. (B) Vectors for both wildtype (WT) and Apobec1-/- (KO) are
compared and the magnitude, angle and variation between them is quantiLied. A
high conLidence edited site possesses a large magnitude angle (left), whereas a
low conLidence site has a low angle (right). (C) Pipeline used for bioinformatic
detection of edited sites.
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Figure 2.2 | Distribution of APOBEC1 editing in BMDMs. Most transcripts
found were edited at a low rate. Transcripts with more than one edited site were
also found.
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Figure 2.3 | Validation of edited targets via Sanger sequencing. Examples of
Sanger sequencing validation of bioinformatically identiLied Apobec1 C to U
editing. (A) Comparison of a fragment of cDNA to gDNA of wildtype and
Apobec1-/- Cd36. The edited site identiLied is highlighted in yellow (left).
Sequences of individual colonies, aligned to the reference genome (right). Dots
indicate matches to the reference sequence whereas mismatches are indicated
with letters. C to T editing events are highlighted in yellow. (B) Fragment of the
transcript App revealing sites of hyperediting. Produced by Claire Hamilton.
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CHAPTER 3. MOLECULAR CONSEQUENCES OF APOBEC1 EDITING

The 3’ UTR region of transcripts is a regulatory hub that controls many processes,
such as nuclear export, stability, degradation and ribosome loading. Therefore, alterations
in this region have the potential to result in regulation of transcript fates. This has been
previously shown to be a possible consequence of ADAR editing81,45; therefore it is
possible that Apobec1 editing has similar consequences.

3.1. APOBEC1 editing in transcript fate
Given that Apobec1 editing in BMDMs did not seem to alter gene expression
globally, I first characterized other potential functions of 3’UTR alterations at the
transcript level. The specificity of APOBEC1 to the 3’ untranslated region of the UTR
suggests that editing plays a regulatory mechanism for transcripts. This has been
previously observed for editing enzymes of the ADAR family. ADAR editing has been
shown to have the potential to alter transcript stability81 and localization45, causing
nuclear retention of the edited transcript. To test whether APOBEC1 editing resulted in
altered localization of transcripts, I designed a cell fractionation experiment to compare
the levels of editing between the cytoplasmic and nuclear fractions. I selected various
transcripts that had different levels of editing at a single site, as well as hyperediting.
After cell fractionation using cell lysis buffers with different composition of surfactants, I
was able to isolate cytoplasm, nucleus and chromatin. Then, I extracted RNA form each
fraction, made cDNA and tested for abundance of each transcript using qPCR.
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In order to compare the frequency of editing at each site in the cytoplasm and
nucleus, I amplified a region surrounding the edited site and submitted individual
bacterial clones for Sanger sequencing. Western blot analysis of the different fractions
using the antibodies for the histone H3 and tubulin confirmed the purity of the nuclear
and cytoplasmic fractions respectively (not shown).
As expected, I found that all edited transcripts in the wildtype sample were edited
in the nucleus. This is consistent with the previously reported mode of action of
APOBEC110. Figure 3.1.1 shows two examples of editing in the different fractions of
wildtype samples. Individual sequences derived from the colony sequencing, amplified
from each of the fraction’s cDNA, were aligned to the reference genome. Using this
data, I quantified the fraction of edited transcripts, counting as edited any transcript with
at least one C-T change in the whole length of the amplified fragment, even if the
previously predicted site did not show editing. As can be seen in Figure 3.1.2.A, the
fraction of edited transcripts in the nucleus is very similar to the cytoplasm, which
indicates that editing does not cause selective retention of edited transcripts in the
nucleus. This is confirmed by the qPCR data in Figure 3.1.2.B, which shows that, even
though the amount of transcripts within the nucleus is higher than in the cytoplasm, there
is no difference between the transcripts of wildtype and Apobec1-/- BMDMs.
An alternative mechanism of transcript regulation that could be affected by
editing is the stability of transcripts. To test whether editing would increase or decrease
transcript stability, I quantified several edited transcripts at different time points upon
addition of actinomycin D to the cell culture, which inhibits transcription. This allows
for evaluation of the decay of transcripts, because no new ones are added to the pool. In
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Figure 3.1.1 | Effect of editing in transcript localization. Aligned sequences of
the PCR fragments ampliﬁed around the edited sites of the Lamp1 and B2m
3’UTRs. The C to T changes, with respect to the genomic sequence, are
highlighted in yellow.
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Figure 3.1.2 | Effect of editing in transcript localization. (A) Quantification of
the fraction of edited transcripts in the nuclear and cytoplasmic cell fractions
(n=3). (B) Relative levels of transcripts in the nuclear and cytoplasmic fractions
of wildtype and Apobec1-/- BMDMs. Transcript levels were normalized to Gapdh.
All error bars represent the standard error of the mean.
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addition to the edited transcripts, I also quantified known stable and unstable transcripts
for comparison. The decay of edited transcripts in both wildtype and Apobec1-/- BMDMs
was quantified via qPCR and plotted. Figure 3.1.3 shows that, as expected, there remains
above 50% of the known stable transcript Atp5a1 after 4 hours after Actinomycin D
addition, whereas there is almost no trace of the unstable transcript Jun at the same time.
When the edited transcripts were examined, I observed that they are stable, such that
there is at least 50% transcript left after 4 hours.
This is interesting, given that it has been demonstrated that Apobec1 directly
binds transcripts with fast turnover, increasing their stability, but in this case, edited
transcripts are long-lived. Perhaps this dynamic is dependent on co-factor utilization.
Interestingly, the stability of Apobec1-/- transcripts is very similar to their wildtype
counterparts, indicating that editing does not modify transcript stability.

3.2. miRNA regulation through editing
APOBEC1-dependent 3′UTR edits were previously described to be preferentially
located in regions of substantial phylogenetic conservation82. Conserved untranslated
regions are also regions of abundant Argonaute (Ago) occupancy and resultant miRNA
targeting83, raising the possibility that APOBEC1 editing might influence transcript
regulation by miRNAs. Our group previously investigated whether the alteration of
3’UTRs leads to the change of microRNA binding sites using the CLIP-seq84 technique.
This consists on immunoprecipitation of the RNA binding protein Argonaute, followed
by protein digestion and library preparation of the resulting fragments. The two types of
RNA obtained after this procedure are miRNAs and mRNAs that are interacting with

29

Adam10

125
100

100

75

75

50

50

25

25

0

0

1

3

4

B2m

125

0

0

100

75

75

50

50

25

25
0

1

2

3

4

Lamp2

125

0

100

75

75

50

50

25

25
0

125

1

2

3

4

Unstable control: Jun

0

100

75

75

50

50

25

25

0

0

1

2

0

3

4

Time (Hours)

0

3

4

1

2

3

4

3

4

Cd36

0

1

2

Stable control: Atp5a1

125

100

2

Lamp1

125

100

0

1

125

100

0

Relative units normalized to T=0

2

App

125

0

1

Apobec1-/-

2

3

4

Wildtype

Figure 3.1.3 | Effect of editing in transcript stability. A time course of
transcript abundance of the indicated edited transcripts after actinomycin-D
treatment of wildtype and Apobec1-/- BMDMs is shown. Atp5a1 and Jun were
used as controls of known stable and labile transcripts, respectively. The red line
marks a 50% reduction (n=3).

30

Argonaute at the moment of cell lysis. The mRNA fragment represents only the fraction
protected by Argonaute, therefore it is possible to bioinformatically identify the possible
miRNA target sites within this footprint and predict which miRNAs are active.
Indeed, high-throughput sequencing of the mRNA and miRNA fragments
revealed that Argonaute significantly bound the subset of transcripts edited by
APOBEC1, even though the comparison of wildtype and Apobec1-/- revealed there was
no differential binding of Argonaute. Therefore, we focused on the subset of 3'UTRs
where Ago occupancy overlapped with edited sites and assigned to these a set of likely
miRNA targets, selected based on miRNA abundance and recently defined rules for
canonical as well as non-canonical binding85. Upon examination of the mRNA from the
footprint, we bioinformatically identified several miRNA binding sites that were
potentially created or destroyed by C to U editing, which are candidates for miRNA
regulation through APOBEC1 editing (Figure 3.2.1).
In order to determine whether a single nucleotide change is sufficient for the
disruption of a miRNA binding site, we performed luciferase assays using a fusion of the
luciferase reporter to the edited version of several 3’UTRs. We cloned edited and
unedited 3′UTRs into dual-luciferase expression vectors and co-transfected them with
their putative miRNA in HEK-293T cells (or an irrelevant control miRNA) in the
absence of APOBEC1. We identified 3′UTRs (e.g. Sptssa and Rac1) where editing
disrupts predicted miRNA-UTR interactions, resulting in de-repression of luciferase
levels in the edited construct, as compared with the unedited construct (Figure 3.2.2).
Two of the four miRNA tested were indeed disrupted by editing. This demonstrated that
for some miRNAs, a C-T change in the binding sequence is sufficient to eliminate the
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Figure 3.2.1 | Putative miRNA targets in APOBEC1-edited regions that
overlap with Ago footprints. “Edited” (with C-to-T mutations reflecting
APOBEC1-dependent changes) and “Unedited” (reflecting the genomic
reference) footprint sequences were scanned for miRNA targets regions (match to
position 2-7, 1-6 or 3-8 of mature miRNA sequence). miRNA targets that would
be created (green) or disrupted (red) by an APOBEC1 editing event are depicted.
Figure produced by Dewi Harjanto.
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interaction between miRNA and mRNA. This serves as proof of concept that
demonstrates that under some circumstances, C to U editing has the ability to disrupt
repression through miRNA binding. However, further research is required to figure out
the rules that govern transcript de-repression and the extent to which edited transcripts
are targets of miRNA binding.

3.3. Editing alters protein production though miRNA independent mechanisms
The overlap between edited sites and Argonaute binding is, however, not
complete. The vast majority of edited transcripts have no predicted Argonaute binding.
Therefore I tested whether editing events that did not alter a putative miRNA binding
sites could also lead to modulation of protein expression. In order to test this, I created
luciferase constructs that contain either the unedited or edited version of several 3’UTRs
fused to the renilla luciferase gene. Additionally, these constructs contain the firefly
luciferase gene, which is co-expressed and used as a transfection control. Each construct
was then introduced into Apobec1-/- BMDMs (which contain the physiologically
relevant milieu of RNA binding factors), to avoid further editing, and luciferase levels
were quantified 24h later. Figure 3.3.1.A shows that from the singly edited constructs,
only the edited 3’ UTR of Cd36 showed a decrease in protein product. On the other hand,
all hyperedited transcripts showed different levels of regulation (Figure 3.3.2A), albeit
small. This experiment also allows us to determine the effect of editing separate from any
alternative activity of APOBEC1, and confirms that the effect in protein modulation is
the direct result of C to U modifications.
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We then tested whether we could observe differences in the endogenous protein
levels of some of the transcripts tested via luciferase assays. We compared the levels of
LAMP1, B2M and CD36 in wildtype and Apobec1-/- BMDMs, via flow cytometry. We
only observed differences in total and cell surface levels of CD36 (Figure 3.3.1.B), which
is consistent with the luciferase experiments. This particular transcript has the special
characteristic that it is both highly edited (80% frequency of editing) and robustly
translated. We therefore speculate that in order to see differences in the expression of
protein products of editing trascripts in the cell, a transcript would need to be both highly
translated and highly edited, as is the case of CD36.
In order to test globally whether edited transcripts result in differences of protein
production, we considered two methods, SILAC and Ribo-seq. SILAC is a method that
uses mass spectrometry to determine the differences between two cell populations, one of
which is labeled with non-radioactive isotopic labeling86. However, the sensitivity of
detection is only very good for highly expressed proteins, and thus cannot access the
entire proteome. Many of the APOBEC1 modified transcripts are not highly expressed,
which is an obstacle for using SILAC.
Ribo-seq is a technique that surveys transcriptome-wide ribosome binding. It uses
high throughput RNA sequencing after polyribosome pool down to determine the ratio
between expressed total RNA and the RNA being translated. This measure has been
shown to be a much better estimation of protein abundance than total RNA87. Riboseq has
the advantge over SILAC of being able to detect small changes and access lowly
expressed transcripts. Given that editing does not happen at an efficiency of 100%, we
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expect that the differences we may find when comparing wildtype vs. Apobec1-/ribosome binding are small.
We therefore performed Ribo-seq using wildtype and Apobec1-/- BMDMs. First,
cell lysate was split in two samples. The first one was treated with nuclease to degrade
RNA unprotected by ribosomes. Then the polyribosomes were selected through column
separation and the protected RNA was extracted for ribosomal RNA depletion, reverse
transcription and library preparation. The second sample was used for total RNA
extraction, followed by ribosomal depletion and library preparation. Both samples were
then sequenced using a lane in the Illumina nextseq and reads were aligned to the
genome. Ribosomal quantification and gene expression were calculated using DEseq.
Translational efficiency was calculated using the coefficient of RPF / mRNA87, and this
was used to asses differential loading between wildtype and Apobec1-/- samples. We
found that the ribo-seq libraries had a lot of variability between samples and were very
prone to batch effects, therefore we decided to analyze the top 25% most expressed
genes. These included the majority of edited transcripts. Figure 3.3.2.B shows there are
no differences in ribosomal binding between wildtype and Apobec1-/- except for
Apobec1; and confirms there are no transcriptional differences between the two
genotypes either.
The lack of translational differences observed in the Ribosome capture assay
indicates that the effect of editing in protein expression is either very minimal, or that at
the level of population, the changes in individual cells with higher degree of editing get
lost in the mix. In the next chapter, the possiblility that cells are heterogeneous in terms
of editing is addressed. On the other hand, an analysis of either protein abundance or
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ribosome binding at the single cell level are experiments which require technology not
available at the moment, so differences at this level will remain to be tested.
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Chapter 4. APOBEC1 editing contributes to cell heterogeneity

APOBEC1 targets 68 different transcripts in resting BMDMs, mostly through
single site editing. These transcripts are targeted with varying frequencies (from ~10%,
our arbitrary lower threshold, to close to 100%). Given that APOBEC1 editing has a
moderate effect on protein levels, we were curious as to whether the varying editing
efficiencies of transcripts at the population level were the result of uniform editing in all
cells, or of high levels of editing in a subset of cells (both possibilities would generate
similar population-wide RNA-seq profiles; Figure 4.1.A). This has been a long-standing
question in the editing field because most of known editing occurs at low frequency for
both ADAR and APOBEC1 editing, rising questions about the biological significance of
editing in aggregate. To explain this phenomenon, two hypotheses have been created.
The first one, proposed by Gommans and Maas, states that such low frequency editing
events may be a way of creating “noise” that perhaps may fulfill a biological function as
an alternative mechanism to genomic-level mutations for probing potentially
advantageous adaptations. Therefore, in their theory, editing at the population level is an
accurate representation of editing in individual cells88. An alternative hypothesis,
presented by Pullirsch and Jantsch, is that RNA editing can diversify cell populations by
actually occurring at a very high frequency in specific subsets of cells89. To distinguish
between them, we used single-cell RNA-Seq to profile editing in individual resting
BMDMs and compared these to a bulk population sample.
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Figure 4.1 | Single cell sequencing. (A) Example plot showing high correlation
between gene expressions of single wildtype vs. Apobec1-/- BMDM cells. (B)
Comparison of the gene expression of the ensemble of all sequenced single cells
vs. the bulk population.

41

4.1. Single cell sequencing
To determine whether there is heterogeneity in terms of editing within the
macrophage population, we performed single-cell high throughput sequencing, using the
C1 system from Fluidigm. Wildtype and Apobec1-/- BMDMs were sorted into C1 chips
where cells were lysed and the RNA was reverse transcribed. Next, single cell libraries
were made using the Illumina Nextera system and sequenced in a lane of an Illumina
Hiseq.
Gene expression of single wildtype cells was compared to their Apobec1-/counterparts. As observed when comparing bulk populations, there is also a high
correlation between the two phenotypes (all possible combinations were analyzed; Figure
4.1.B shows an example of one such pair).
The comparison of the gene expression levels of bulk RNA-Seq (of a population
of BMDMs) and the ensemble of all single cell replicates showed a tight correlation
(r>0.99; Figure 4.1.C), indicating that the gene expression signature obtained from the
single cells is a good representation of the bulk population. This also shows an apparent
lack of heterogeneity at the transcript expression level in un-stimulated single cells. This
has precedent in bone marrow-derived DCs, where resting cells start off as
transcriptionally homogeneous, with variation at the level of expression introduced
shortly after stimulation90.
Furthermore, highly expressed transcripts, such as B2m showed little variability in
expression levels in single cell libraries. However, that is not the case for most edited
transcripts (Figure 4.2.1, left); the mid and lowest expressed transcripts showed the most
variability between cells, which is consistent with previous reports91.
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Figure 4.2.1 | Editing distribution in single BMDMs. Coverage (left) and
editing rates (right) for high confidence C-to-U edited sites in the 24 single-cell
and bulk macrophage RNA-seq data sets. Bottom: expression levels of
APOBEC1 in transcript per million. Sites are sorted in order of descending bulk
editing rate. Produced by Dewi Harjanto.
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4.2. Analysis of the variability of editing rates per site across single cells
Single cell sequencing has been shown to have several characteristics. Due to the
small amount of starting material and the efficiency of reverse transcription, it is not
possible to access the entire transcriptome, which results in an underrepresentation of
lowly expressed transcripts. Also, the reverse transcription is primed with polyA oligos,
therefore the reads are enriched at the 3’ end of transcripts. These characteristics are not
problematic when these reads are used for gene expression analysis92. However, editing
detection requires sites to be well covered and reads to be properly mapped. The low
capture efficiency in single cell sequencing, estimated at around 20%93, is the major
obstacle for using editing detection algorithms, especially for lowly edited or expressed
transcripts.
Due to these sampling issues, if a site is not edited, there could be two
possibilities: that the site is genuinely not edited in the cell’s transcriptome; or that the
edited transcripts were present but were not captured during library preparation and
sequencing. When examining editing at the high confidence sites identified from the bulk
RNA-seq, across the single cells, we observed that, editing is present in at least one of the
cells (402 of the 410 sites were covered in at least one cell and 22 of those sites was
edited in at least one cell; Figure 4.2.1, left). However, editing levels did not necessarily
correlate with APOBEC1 levels (Figure 4.2.1, right-bottom). Within these sites, we can
also observe a wide range of editing rates. For example, the site in the Cybb transcript
(indicated in Figure 4.2.1, right), which is covered uniformly in all cells, is edited in
61.5% of the reads in cell 6 while it isn’t edited at all in 11 other cells (compared to just
23% in the bulk experiment).
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Whereas it would seem from looking at Figure 4.2.1 that there is indeed
heterogeneity in terms of editing among the single cells, the stochasticity inherent in the
single cell RNA-seq method has to be accounted for. To ascertain variability within the
APOBEC1-mediated editing rates from single cells, in comparison to the bulk editing
rates recovered form populations of cells, a more sophisticated statistical method had to
be developed. In order to do this, we collaborated with a group of statisticians at the
University of Warwick to model the level of variability of editing rates per site across
∗

single cells and in bulk samples. They created a hierarchical Bayesian method80 to model
the behavior of variable and homogeneous cells, and determined the profiles that each
scenario would result in (Figure 4.2.2). Essentially, a population with high variability
would have a high variability in the posterior distribution and a wide range of p values
(Figure 4.2.2, top), whereas a homogeneous population would have a low posterior
variance and narrow p values (Figure 4.2.2, bottom). When comparing these to the
experimental data, they determined that there is a wide range of variability: they could
find instances of transcripts edited with low, mid and high variance across cells (Figure
4.2.3. A, B and C, respectively).

4.3. Experimental validation of editing heterogeneity
To validate the predictions made by the model, we designed an RT-PCR
amplification method to specifically look at different regions of transcripts that are
editable. In order to carefully do molecular quantification of the edited transcripts, I
designed gene specific RT-primers with a 6 nucleotide barcode, which are sufficient to
∗

Theodore Papamarkou, Chris J. Oates & Anastasia Papavasiliou; Department of Statistics, University of
Warwick, UK.
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Figure 4.2.2 | Effect of changing the levels of variance on model. Histograms
of variance of editing rates (left), editing rates (middle) for two artificial data
sets, one with high editing rate variance (top); and the other with low editing rate
variance (bottom). Produced by Dewi Harjanto.
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Figure 4.2.3 | Application of the Bayesian model to macrophages.
Simulations ran on 24 single-cell data for B2m, Anxa5 and Cybb. Left:
histograms of variance of editing rates, across all 24 cells; right: histograms of
editing rates, denoting the distributions of editing rates for each cell (each cell is
labeled with a different color). Produced by Dewi Harjanto.
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capture 4096 unique transcripts, a more than adequate amount to characterize the
diversity within a single cell93. The fragments were then cloned into bacteria and
sequenced using Sanger sequencing. Using the barcodes, I could discriminate fragments
that are the result of PCR duplication and remove them from the analysis. This allowed
us to examine the different sites with substantial depth, which is the main limitation of
the high-throughput approach. Figure 4.3.1 shows the location of the edited sites in
several single cells. The edited transcripts are labeled in red. The results from this
experiment align well with the model predictions. In the case of Cybb, for which the
posterior distribution in the model suggests high variability, we observed that there exist
cells that have very high levels of editing (Figure 4.3.1.C, cells #1, 2 and 6) along with
ones very low levels (Figure 4.3.1.C, cells #4, 5 and 7). Similarly, in the case of B2m and
Anxa5, for which the model predicted lower variability, we can see that cells are roughly
uniformly edited (Figure 4.3.1.A and B).
When we examined the whole of the amplified region (300nt fragments; Figure
4.3.2), we were able to identify editing that occurred at different sites from the
bioinformatically determined ones. In the case of Anxa5, we observed that there is
substantial editing in these alternative sites, which was not apparent from the bulk
sequencing. This is perhaps because of the stringent filters in the bioinformatics
algorithms used to identify editing. Transcripts where editing exists in an alternative site
are also labeled in red on Figure 4.3.2.
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Figure 4.3.1 | Validation of model predictions using targeted amplification of
editable sites from single cells. Sequence alignments from targeted RT–PCR
amplification and Sanger sequencing of bacterial colonies for B2m, Anxa5 and
Cybb transcripts from gDNA and cDNA from a bulk sample and cDNA of single
cells. Alignments are colour-coded to indicate whether the sequence aligned
contained (red) or lacked (grey) editing in the length of the amplicon.
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Figure 4.3.2 | Editing at sites alternative to the bioinformatically identified
site. The alignment of a single cell is shown for B2m, Anxa5 and Cybb. The site
shown in figure # is shown in grey. Alternative C to T changes are shown as T’s
within the alignments.
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CHAPTER 5. FUNCTIONAL CONSEQUENCES OF APOBEC1 EDITING IN
MONOCYTES

At a molecular level, editing is involved in the modulation of protein expression,
either through the modification of miRNA binding or through alternative mechanisms.
This is significant because even though editing occurs in low frequency at the population
level, there is substantial variability between cells, raising the possibility that subsets of
the population have specific characteristics. This variability between cells is reminiscent
of the variability that has been described for monocyte populations and their plasticity,
which allows them to respond to fluctuating environmental cues94,95. This is crucial to the
maintanance of homeostasis as monocytes perform many crucial roles for the organism
such as removal of debris and the production of tissue maintanance factors.
However, they also have the ability to react towards foreign antigens and help
orchestrate an inflammatory response. Finally, in order to protect the body from
exaggerated inflammatory responses, they are also invoved in the repression of the
response and tissue repair. It has been long though that these responses are performed by
subsets of macrophages that have one of two phenotypes, M1 (inflammatory or
classically activated macrophages) or M2 (homeostatic or alternatively activated
macrophages). However, it is becoming clear that there is more of a spectrum rather than
a binary classification for monocytes and that these cells are very plastic, being ablet to
change from one phenotype to another. We therefore evaluated whether the lack of
editing had consequences in the activity of macrophages.
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Previous investigations of the functional consequences of RNA editing have
focused on instances where transcripts are edited with very high frequency and with clear
biological implications (e.g. APOBEC1 editing of Apolipoprotein B96,97). However, the
collective functional consequence of targeting a large number of transcripts has never
been examined. In order to find relevant processes that could be modulated by editing, I
looked for pathway enrichment of edited transcripts using the online database DAVID
(Broad Institute). Because this database is a repository of all genes regardless of origin, it
identifies non macophage-specific pathways, although many of the pathways identified
are pertinent to immune cells. APOBEC1 edited transcripts in BMDMs encode proteins
important for lysosome maturation (e.g. Lamp1, Lamp2, Atp6ap1) and phagocytosis, as
well as proteins important for migration (e.g. Rac1, Kras, Pak2, Brb2; Table 5.1). Given
that editing can affect protein abundance, we asked whether small alterations in the levels
of such proteins could collectively alter cell physiology. Therefore, we assessed the
relative performance of wildtype and Apobec1-/- BMDMs in both phagocytosis and
migration.

5.1. Editing deficient BMDMs display altered migration and phagocytic capacities
One of the early consequences of chemokine signaling in BMDMs is directed cell
migration. In order to test whether migration is altered in editing-deficient BMDMs, we
designed a migration test where BMDMs are placed in the upper chamber of a two
chamber culture dish. We determined from the RNA-seq data that the highest expressed
chemokine receptor in BMDMs is CXCR4, whose preferential ligand is CXCL12 (also
known as stromal-derived-factor-1). Expression of CXCR4 was confirmed via flow
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Table 5.1 | Pathway enrichment analysis using the subset of edited
transcripts. Sites found in BMDM were fed to the pathway identification
website DAVID from the Broad Institute. Significant pathways related to immune
cell activity are presented.
Term
Lysosome
B cell receptor
signaling pathway
VEGF signaling
pathway
T cell receptor
signaling pathway

PValue
3.0E-04

Genes
CTSL, LAMP2, SLC17A5, AP1S2, IDS,
GNPTAB, TPP1, ATP6AP1, ASAH1, CTSF

NRAS, KRAS, GRB2, RAC1, PPP3CB,
PPP3R1, PPP3CA, NFATC3
NRAS, KRAS, RAC1, PPP3CB, PPP3R1,
2.5E-03
PPP3CA, NFATC3
NRAS, KRAS, PAK2, GRB2, PPP3CB,
5.6E-03
PPP3R1, PPP3CA, NFATC3
6.0E-04

Natural killer cell
mediated cytotoxicity

6.7E-03

NRAS, KRAS, GRB2, RAC1, PPP3CB,
PPP3R1, PPP3CA, NFATC3

Sphingolipid
metabolism

6.9E-03 SGPL1, SPTLC1, SGPP1, ASAH1, DEGS1

Fold
Enrichment

FDR

4.5

0.338

5.4

0.681

5.0

2.849

3.7

6.248

3.5

7.438

6.4

7.670

2.2

22.920

2.4

43.365

Chemokine signaling
pathway

NRAS, KRAS, PAK2, GRB2, RAC1, TGFBR2,
2.2E-02 PPP3CB, PPP3R1, PPP3CA, PRKACB,
GADD45A
NRAS, KRAS, GRB2, GNG10, PREX1, RAC1,
4.8E-02
PRKACB, CCL5

N-Glycan biosynthesis

5.1E-02 STT3B, MAN2A1, MGAT2, FUT8

4.7

45.240

PPAR signaling
pathway

5.6E-02 LPL, CD36, GYK, ACSL4, CPT1A

3.4

48.305

Apoptosis

7.4E-02 CASP6, PPP3CB, PPP3R1, PPP3CA, PRKACB

3.1

58.746

Cell cycle

8.5E-02

2.5

63.660

MAPK signaling
pathway

E2F4, HDAC2, RAD21, RBL2, MCM4,
GADD45A
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cytometry in both wildtype and Apobec1-/- BMDMs, which didn not display differences
in cell surface expression of the receptor. Therefore we chose to teste migration towards
this chemokine. Briefly, different concentrations of the chemokine CXCL12 were placed
in the lower chambers of a two chamber culture dish and the BMDMs were placed in the
top chambers. Media without serum was used as a control for basal migration and the
amount of migrated cells was determined 4h later using a fluorescent dye that binds to
DNA. The median fluorescence intensity is directly correlated to the amount of DNA in
each well, which is a good reflection of the number of migrated cells. Migration is
reported as the chemokine index, which is a relative measurement that is calculated
normalizing to the basal migration. As shown in Figure 5.1.A, APOBEC1-deficient
macrophages have a very reduced migration capability. We speculate that because there
are no differences in CXCR4 receptor expression, the altered migration phenotype of
Apobec1-/- BMDMs is the result of differences in downstream signalling molecules (e.g.
Ras) or cytoskeleton remodelation (e.g. Rac), both of which are good starting points for
future studies.
To test phagocytosis, we added pHrodo-labeled S. aureus particles at two
different multiplicities of infection (MOI) to BMDMs cultures. These particles are
colorless until they reach the acidic environment of the lysosome, where they fluoresce.
Phagocytosis can thus be directly quantified by flow cytometry 20 min later.
Surprisingly, Apobec1-/- BMDMs showed an increased amount of particle uptake,
compared to wildtype counterparts (Figure 5.1.B), therefore, lack of editing leads to
increased phagocytosis. It has been shown before that an over-abundance of LAMP1 and
of other proteins involved in phagosome maturation leads to an increase in phagosome
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Figure 5.1 | APOBEC1 is required for the proper phagocytosis and
migration in vitro. (A) Quantification of migration towards CXCL12 (also
known as SDF-1). Error bars represent the standard error of the mean, statistical
analysis was performed using the multiple measured one-way analysis of
variance, followed by a t test with Bonferroni’s correction; n=3; *p< 0.05, **p<
0.01, ***p< 0.0001). (B) Phagocytosis of S. aureus pHrodo particles (aggregate
of n=5). Error bars represent the standard error of the mean; statistical
significance was obtained using a t-test. MOI stands for multiplicity of infection.
(A) was done in collaboration with Yamina Berchiche.
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maturation98. We speculate that this may be one of the reasons why Apobec1-/- cells (or a
subset of them) that potentially have increased levels of Lamp1, have an increased
capacity to uptake the beads.
Interestingly, Apobec1-/- BMDMs are poor at an essential activity of
macrophages but not at an equally fundamental one, specially because the two activities,
even though independent from each other, are very related (e.g. cells need to migrate to
sites of infection in order to ingest bacterial invaders). We can speculate that this could be
the result of the variability of editing between the cells and how this affects specific
pathways in different cell subsets. However, this remains to be tested.

5.2. Editing is necessary for proper monocyte differentiation
The differences in macrophage activity observed in vitro suggest that Apobec1-/mice ought to have alterations in monocyte activity. In order to find clues for Apobec1mediated regulation in the physiology if mice, I performed a phenotypic characterization
analysis of Apobec1-/- mice, that included a complete blood count, blood chemistry and
∗

organ dissection and staining (results not shown). I also characterized the different
immune populations in bone marrow, blood, and spleen via flow cytometry (not shown).
With all of this information, I concluded that, besides the already published increase in
the low density lipoprotein fraction and a reduction in high density lipoprotein cholesterol
resulting from impaired ApoB editing60,99, there are no additional physiological
differences in the Apobec1-/- mice when compared to their wildtype counterparts.
∗

This work was done by the Laboratory of Comparative Pathology at Memorial Sloan-Kettering Cancer
Center
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However, any differences in monocytes in vivo could be obscured as a result of
compensation mechanisms. In order to study monocytes in vivo and have a direct
comparison of wildtype and Apobec1-/- monocytes, which have been differentiated in the
same milieu, we turned to a competitive reconstitution experiment. This experiment
allows us to look at monocytes developing before compensations mechanisms can kick in
and also has the advantage that reconstituting wildtype mice allows for proper
APOBEC1-editing in intestine and liver. This allows us to isolate cell-autonomous,
APOBEC1-dependent effects on the monocyte lineage in the absence of other known
APOBEC1 related phenotypes (e.g. intestinal editing of Apolipoprotein B).
The competitive reconstitution experiment consists of placing Apobec1-/monocytes along with their wildtype counterparts in a wildtype environment in vivo, thus
having a direct comparison of their activity when challenged. One of the ways in which
we can obtain both populations within wildtype mice is through the creation of chimeras.
This can be achieved through bone marrow reconstitution of irradiated mice with bone
marrow progenitor cells. After these chimeric mice establish the monocyte populations,
we can challenge them and test macrophage differential activity.
Specifically, I injected equal numbers of bone marrow progenitors from wildtype
(CD45.1) and Apobec1-/- (CD45.2) bone marrow into lethally irradiated syngeneic hosts
and tested for reconstitution of monocytic populations in spleen via flow cytometry
(Figure 5.2.1). The reconstitution of monocytes is one of the earliest events after bone
marrow transplantation; we observed monocyte populations in spleen as early as 3 weeks
(Figure 5.2.2.A). However, other cells, such as B and T cells have much longer
reconstitution times.
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Figure 5.2.1 | Analysis of spleen chimeras. Splenocytes were stained with
a cocktail of antibodies and analyzed via flow cytometry. The gating used
to separate the populations are indicated.
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Figure 5.2.2 | APOBEC1 deficient mice have altered monocyte populations.
(A) Analysis of spleen in radiation chimeras reconstituted with an equal number
of wildtype and Apobec1-/- lineage-negative bone marrow progenitors (n=6). (B)
APOBEC1 expression in sorted monocyte progenitors, relative to Gapdh
expression. MDP: monocyte dendritic cell progenitor; cMOP: common monocyte
progenitor. (E) Analysis of bone marrow monocyte progenitor populations in
radiation chimeras reconstituted with an equal numbers of wildtype and
Apobec1-/- progenitor cells, 6 weeks after transplant (n=6).
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Surprisingly, when we compared the ability of each progenitor to reconstitute
monocyte populations in spleen, we found that, even though the progenitors were mixed
in a 1:1 ratio, the Apobec1-/- progenitors outcompeted their wildtype counterparts and
gave rise to significantly increased numbers of M1-like (Ly6C+) monocytes in the spleen
at 6 weeks, a trend that initiated at 3 weeks (Figure 4.2.2.A). Meanwhile, the frequency
of the other major type of monocyte, M2-like (Ly6C-), was not altered (Figure 5.2.2.A).
In a separate experiment, we also irradiated Apobec1-/- and Apobec1+/- mice and
reconstituted them with a 1:1 mix of progenitors. Under these conditions, the Apobec1-/progenitors also generated increased monocytic populations in spleen (not shown). This
demonstrates there are no significant numbers of radiation-resistant cells at 3 weeks posttransplant, which could bias the results of the reconstitution. Also, this indicates that the
effect is cell intrinsic.
To test whether the increase in Ly6C+ monocytes is due to an increase in their
proliferative capacity, I tested for expression of Ki-67, a nuclear marker specifically
found in proliferating cell100, via flow cytometry. I did not observe Ki-67 expression in
Ly6C+ monocytes (not shown), which suggests these cells are not proliferating.
Alternatively, the increased number of Apobec1-/- Ly6c+ cells in spleen could be the
result of increased output from the progenitor cells, increased cell division of mature
monocytes or increased migration of monocytes into the spleen. We had previously
observed that BMDMs have decreased migratory ability towards CCL12; however, this
seems not to be the case in vivo. This could be the result of differences between
monocytes and BMDMs, which are an artificially derived mature form of macrophages,
as compared to monocytes, which are a more immature subset. However, it could also be
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that the migration phenotype is restricted to signaling through CXCR4, which has been
shown to mediate retention of monocytes in the bone marrow101. If this mechanism of
retention is indeed impaired in Apobec1-/- monocytes, it is possible they would exhibit
increased exit from the bone marrow.
Alternatively, APOBEC1 could be regulating the developmental progression of
specific subsets of cells in the bone marrow. In order to test this I quantified the
expression of APOBEC1 in monocyte subsets and bone marrow monocyte progenitors
via qPCR, in sorted populations. APOBEC1 is expressed early in monocyte
differentiation, and its transcript levels are highest in the common monocyte progenitor
(cMOP) cells (Figure 5.2.2.B). This could mean that in vivo, APOBEC1’s function is
involved in monocyte differentiation. To test whether the increase of Ly6C+ monocytes
is the result of increased progenitor cells, I quantified the number of these progenitors in
bone marrow after reconstitution. Apobec1-/- cMOP cells outcompeted their wildtype
counterparts at 6 weeks after transplant (Figure 5.2.2.C), confirming that APOBEC1
plays a role in properly generating monocyte populations at various points during
differentiation. Further experiments to catalog edited targets in cMOP cells are required
to identify the mechanism through which editing modifies these progenitors.

5.3. Editing is dispensable for initiating a strong inflammatory response
Given that we observed preferential phagocytosis in vitro and creation of
inflammatory-like monocytes in vivo, we speculated APOBEC1 editing could be
involved in the establishment of the inflammatory response in general. To test this, I
assayed the ability of wildtype and Apobec1-/- macrophages to respond to
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lipopolysaccharide (LPS) and in vitro and in vivo. LPS is an endotoxin consisting of a
lipid and a polysaccharide with an O-antigen, found in the outer layer of Gram-negative
bacteria. LPS binds to the CD14/TLR4/MD2 receptor complex in several immune cells
including macrophages. This results in the production of pro-inflammatory cytokines,
nitric oxide and eicosanoids.
To test the ability of wildtype and Apobec1-/- BMDMs to mount an inflammatory
response, I primed cells with IFNγ for 2 hours, followed by addition of LPS, and
quantified the expression of APOBEC1 and several pro-inflammatory cytokines at
several time points via qPCR. I also tested for the production of nitrogen reactive species,
via the quantification of nitric oxide in the media after IFNγ + LPS stimulation. I
observed that the expression of Apobec1 increased 2 fold after 18h of LPS stimulation
and continued to increase over time (Figure 5.3.A). However, this was not accompanied
by differential expression of Nos2, nor the pro-inflammatory cytokines Ccl5, Il12b or
Il1a (not shown). The expression of the pro-inflammatory cytokine Tnfa seemed to be
transiently induced at an early time point in Apobec1-/- BMDMs (Figure 5.3.B).
To test whether there is differential production of cytokines, I performed a
quantification assay using the Luminex technology. This consists of capturing free
cytokines in the supernatant of the cell culture via beads coupled with specific antibodies.
Next, these beads are incubated with fluorophores that aid in the determination of
cytokine concentration. Luminex assays can be easily multiplexed, giving the ability to
test for a large panel of cytokines at a time. I used the Cytokine 20-Plex Mouse Panel
(Thermo Fisher Scientific), which includes a wide variety of cytokines as well as
chemokines and growth factors (GM-CSF, IFN-γ, Il-1α, IL-1β, IL-2, IL-4, IL-5, IL-6,
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Figure 5.3 | APOBEC1 deficient BMDMs do not have enhanced ability to
establish an inflammatory response. (A) Analysis of Apobec1 expression in
wildtype BMDMs after IFN + LPS stimulation, via qPCR (n=3). (B) Relative
expression of Tnfa at different timepoints after stimulation with IFN + LPS. Both
Apobec1 and Tnfa were normalized using Rpl32. (C) Quantification of TNFa
protein in the supernatatnt of cells after 24 h of stimulation with IFNg + LPS (via
Luminex; n=9).
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IL-10, IL-12 (p40/p70), IL-13, IL-17, TNFα, IP-10, KC, MCP-1, MIG, MIP-1α, FGFbasic and VEGF). Using this technology, I observed that there were no differences in the
amount of cytokines secreted by Apobec1-/- BMDMs in comparison to their wildtype
counterparts (e.g. TNFα is presented in Figure 5.3.C). Furthermore, I found that resting
Apobec1-/- BMDMs did not express pro-inflammatory cytokines.
Additionally, I tested the fitness of monocytes to incite an inflammatory response
in vivo using two models of acute inflammation: intraperitoneal LPS and zymosan
intraperitoneal injection. Both of these are particles found on bacterial outer membranes
and yeast, respectively, and are identified by receptors in macrophages. Upon recognition
of these particles, macrophages secrete inflammatory cytokines that are able to recruit
more cells into the peritoneum. Depending on the dose utilized, the response can be
cleared in 48 to 72 hours. I observed that wildtype and Apobec1-/- mice have a similar
ability to induce an inflammatory response in the peritoneum: both mice have equal
ability to recruit cells into the peritoneum, produce sufficient levels of inflammatory
cytokines, and resolve the inflammation to allow for survival (data not shown). This is
consistent with the in vitro results presented above. However, they seem inconsistent with
the results that show a higher establishment of Ly6C+ pro-inflammatory monocytes in
Apobec1-/-.
This indicates that either there is no difference between the two genotypes, or that
the time scale that I looked at is off. Another alternative is that the overwhelming amount
of inflammation produced by the LPS and zymosan very highly activate the system and
mask subtle differences.
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5.4. Editing in microglia
In an effort to continue with the characterization of inflammation in other organs,
I collaborated with Dr. Karen Bulloch’s group at the Rockefeller University to study
∗

brain alterations . Dr. Bulloch’s group is interested in studying brain immunology and
brain pathologies in aging. They examined the brains of 3 month and 1-year-old wildtype
and Apobec1-/- mice. They only identified alterations in the brains of aged Apobec1-/-.
These alterations consisted of clustering of cells that stained positive for Iba-1 (a marker
that in the brain is specific of microglia), indicative of activated microglia (not shown).
This was accompanied by an increase in pro-inflammatory cytokine expression (from
whole cortex and hippocampus extracts; not shown).
In order to relate these findings to APOBEC1 editing, we first looked in the
literature for gene expression datasets in brain cell subsets to identify cells expressing
APOBEC1 within the brain. We examined the RNA-seq dataset from Zhang and
collaborators102, who purified neurons, astrocytes, microglia, endothelial cells, pericytes,
and various maturation states of oligodendrocytes from mouse cortex. We found the
highest expression of APOBEC1 is within microglia and astrocytes. However, when we
searched for the known APOBEC1 cofactors ACF and RBM47, we found that they were
exclusively expressed in microglia, making this cell type the most likely candidate where
editing might be found. These microglial cells were isolated from mouse brains using a
two step approach, first brains were perfused with PBS in order to eliminate
contaminating monocytes from the periphery, then microglia cells were isolated using

∗
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CD45 antibodies. However, CD45 is a cell marker present in many subtypes of immune
cells. Previous work from Dr. Bulloch’s lab, using a CD11c-egfp transgenic mouse, has
demonstrated that mouse olfactory bulb CD45+ subset also includes brain dendritic cells,
which can be characterized their expression of CD45 and CD11b, namely P1 (CD45int
CD11bhi), P2 (CD45hi CD11bhi) and P3 (CD45hi CD11bint)103. Therefore, we sought to
characterize the expression of APOBEC1 in two main subsets of CD45 expressing cells
(CD45+CD11b+CD11c+ and CD45+CD11b+CD11c-) within cortex and hippocampus,
where the brain alterations were originally described.
In order to identify editing in these subsets, we first sorted CD45+CD11b+CD11c+
(CD11c+ MG) and CD45+CD11b+CD11c- (CD11c- MG) cells from wildtype and
Apobec1-/- mice, and performed RNA extraction and library preparation to perform high
throughput RNA-sequencing. Interestingly, using gene expression analysis, we did not
find differential gene expression between wildtype and Apobec1-/- in either the CD11c+
MG or CD11c- MG subsets (not shown). This is very similar to my observations in
BMDMs derived from the same genotypes (as mentioned in Chapter 2).
In order to detect editing in the CD11c+ MG or CD11c- MG datasets, we used
our editing detection algorithm. Surprisingly, the algorithms were only able to identify a
few sites that were modestly edited. In order to validate these sites, I tested them through
PCR amplification and Sanger sequencing, in a similar way as shown in figure 2.3;
however, I could not validate any of the sites.
I then decided to query the sites that were identified in BMDMs, to see if they
could also be edited in the CD11c+ MG and CD11c- MG populations. To accomplish
this, I looked at specific edited sites in several transcripts via PCR amplification and high
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throughput sequencing (high throughput amplicon sequencing), which allowed me to
access each site with substantially more depth than regular high throughput RNAsequencing. I chose several sites that are edited in BMDMs and expressed in the CD11c+
and CD11c- MGs (Table 5.2). Indeed I observed that the editing rate at these sites is very
small in both populations of microglia, which is consistent with the failure of the
algorithm to identify them.
As I have posed before (in chapter 4), low levels of editing are not necessarily the
representation of editing in single cells within a population. Given that editing is variable
within BMDMs it is possible that it would also be within individual microglial cells. This
would suggest that editing is not present in all microglia and that instead, subsets of the
microglial population could exist which harbor high levels of editing. In order to test for
this possibility, I examined a known subpopulation of CD11c+ cells that are
characterized by the expression of the CD103 marker. These cells are highly enriched in
olfactory bulb after intranasal infection with VSV103, therefore the cells were collected
after VSV infection and RNA was extracted (this procedure was done previously for a
project unrelated to this work). I used the RNA to do a spot check of editing in this
population, amplifying two of the most highly edited targets in BMDMs, B2m and
Lamp2, in a similar way as described for figure 2.3. I observed that in contrast to CD11c+
MG, which displayed a very small amount of editing, the subpopulation of
CD11c+CD103+ cells had a high amount of editing (Figure 5.4). This shows that in fact
different subpopulations of microglia demonstrate different levels of editing, therefore
there is a possibility that the lack of APOBEC1 editing of a subset of cells may be
involved in the clustering of microglia and inflammation phenotype observed in
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Apobec1-/- aged brains. Further work is needed to identify the specific population(s) of
microglia, which harbors APOBEC1 editing in aged brains, and to link those specific
populations to the phenotype observed.
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Table 5.2 | Amplicon sequencing-based validation of putative edited genes.
Sites found in BMDM were amplified in both CD11c+ and CD11c- MG and
sequenced and the frequency of C to T changes was quantified.
Table 1a | Validated edited sites in column-separated CD11c+ cells.

Amplicon sequencing on cDNA
Region

UTR3
UTR3
UTR3
UTR3
UTR3
UTR3
UTR3
UTR3
UTR3
UTR3
UTR3
UTR3
UTR3
UTR3
exonic
exonic

Gene

Anxa5
B2m
B2m
B2m
B2m
B2m
B2m
B2m
Lamp2
Lamp2
Sh3bgrl
Sh3bgrl
Sh3bgrl
Dennd1b
Med13l
Pki3r4

Chromosome Coordinate

chr3
chr2
chr2
chr2
chr2
chr2
chr2
chr2
chrX
chrX
chrX
chrX
chrX
chr1
chr5
chr9

36449030
122152613
122152682
122152740
122152742
122152787
122152804
122152902
38421317
38421565
109160420
109160354
109160178
139175650
118754418
105650713

Reads
Coverage

Frequency Frequency of
of C to T
Non-C to T

354443
91
452558
444796
446438
669269
675429
416611
125796
129390
22804
25647
13610
132688
163564
2585

1.40%
1.10%
1.20%
7.60%
1.50%
2.90%
3.20%
6.40%
1.00%
1.30%
4.10%
3.90%
2.10%
1.60%
1.10%
1.30%

0.00%
0.00%
0.00%
0.00%
0.10%
0.20%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%

RNA -sequencing
Reads
Coverage
72
31
17854
17223
16235
8190
9610
10425
666
893
16
23
18
5
39
12

Frequency
of C to T
2.80%
0.00%
0.60%
5.70%
1.00%
1.40%
1.90%
3.90%
0.50%
2.00%
12.50%
0.00%
0.00%
0.00%
0.00%
0.00%

Amplicon sequencing on DNA
Reads
Coverage
14530
13468
13680
13627
13628
20889
20914
10358
30059
31356
110353
112949
59802
52069
70500
1

Frequency Frequency of
of C to T
Non-C to T
0.1%
1.6%
0.0%
0.2%
0.1%
0.3%
0.3%
1.0%
0.0%
0.0%
0.0%
0.0%
2.0%
0.0%
0.0%
0.0%

0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
0.1%
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%

Amplicon sequencing was also performed in 9 other genes with no editing detected (Sec24a, Rapgef5, Tfrc, Semad6, Psmc3ip, Zfp318, Dnajc1, Dcun1d4 and Gab2).

Table 1b | Validated edited sites in column-separated CD11c- cells.

Amplicon sequencing on cDNA
Region
UTR3
UTR3
UTR3
UTR3
UTR3
UTR3
UTR3
UTR3
UTR3
UTR3
UTR3
UTR3
UTR3
UTR3

Gene
Anxa5
Anxa5
B2m
B2m
B2m
B2m
B2m
B2m
B2m
Lamp2
Lamp2
Lamp2
Rac1
Jag1

Chromosome Coordinate
chr3
chr3
chr2
chr2
chr2
chr2
chr2
chr2
chr2
chrX
chrX
chrX
chr5
chr2

36449225
36449030
122152902
122152740
122152804
122152787
122152742
122152682
122152871
38421565
38421618
38421317
143505935
137081857

Reads
Coverage
84085
78293
180151
192034
282971
283924
193011
195676
177490
23541
23633
20690
97069
122649

Frequency Frequency of
of C to T
Non-C to T
1.80%
1.50%
7.30%
5.90%
3.40%
2.30%
1.40%
1.30%
1.10%
1.70%
1.10%
1.10%
1.60%
2.00%

0.00%
0.00%
0.00%
0.00%
0.20%
0.10%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%

RNA -sequencing
Reads
Coverage
256
120
9715
15585
7405
6187
14523
16883
5569
1041
1649
751
365
0

Frequency
of C to T
0.00%
0.00%
4.80%
6.80%
2.70%
2.10%
1.50%
0.90%
0.90%
0.90%
0.10%
0.80%
0.80%
nan

Amplicon sequencing on DNA
Reads
Coverage
15824
14530
10358
13627
20914
20889
13628
13680
19000
31356
31379
30059
1208
24

Frequency Frequency of
of C to T
Non-C to T
0.0%
0.1%
1.0%
0.2%
0.3%
0.3%
0.1%
0.0%
0.2%
0.0%
0.0%
0.0%
0.6%
4.2%

Amplicon sequencing was also performed in 14 other genes with no editing detected (Cluh, Polrmt, Fut8, Alg12, Enpp1, Lpp, Sepn1, Vamp4, Bms1, D7ertd443e, Usp48, Socs4,
Ncapd3 and Mast2).
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0.0%
0.0%
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0.0%
0.0%
0.0%
0.2%
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0.0%
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Figure 5.4 | APOBEC1 editing is present in a subset of microglial cells
characterized by CD11c+ CD103+ expression. C to T RNA editing events can
be seen in the B2M (A) and Lamp2 (B) transcripts of subclones obtained from
CD45intCd11b+EYFP+ cells from Cd11c-EYFP mice.
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CHAPTER 6. DISCUSSION

At the beginning of my work, the role of Apobec1, except for a couple of
exceptions, seemed to be constrained to the intestine and exquisitely confined to lipid
transport and metabolism through editing of the ApoB transcript. With the advent of high
throughput sequencing technologies, our group was able to identify additional targets of
Apobec1 within the intestine and in several cells of the immune system, especially in
macrophages. However, the significance of these findings was absent, as were the
functional consequences of these modifications. This is a common theme for ADAR
targets as well, since for most such transcripts, especially the ones that do not result in
changes in coding regions, the functional consequences remain murky.
Upon close examination of APOBEC1 targeted transcripts I was able to
demonstrate that Apobec1 editing has a significant role outside of the intestine as it
confers macrophages the ability to maintain proper homeostasis. These results were
presented throughout my thesis and will be discussed in depth here.

6.1. Comparison of wildtype vs. Apobec1-/- macrophages
My experiments demonstrated that although there are no differences in transcript
processing (transport, stability and differential expression) between the wildtype and
Apobec1-/- genotypes, APOBEC1 regulates protein expression in miRNA dependent and
independent ways, which are the direct consequence of editing. As noted in figures 3.1.1
and 3.1.2, Apobec1 edited transcripts did not display selective nuclear retention, in
comparison to their unedited counterparts. This is a process that for ADAR, has been
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proposed to be a molecular consequence of editing, which is mediated through binding of
an RNA binding protein (p54), which presumably recognizes the tertiary structure of he
dsRNA. In the case of Apobec1 editing, we do not expect edited regions to have specific
tertiary structures due to their AU rich nature. However, differential RNA protein binding
between edited and unedited transcripts is still to be investigated.
Stabilization of transcripts is the second process that has been proposed for
ADAR editing, therefore I decided to test whether this is a general phenomenon that
results from editing. Also, Apobec1, in its role as an RNA binding protein, has been
shown to increase the stability of several transcripts with AU rich 3’UTRs, such as COX2
and TNF-α. Figure 3.1.3 shows that Apobec1 edited mRNAs have a high stability, even
when Apobec1 is absent from the milieu (in the Apobec1-/- sample). This indicates that
perhaps Apobec1 transcript stabilization is separate form its role in editing.
I also showed a significant overlap between Argonaute occupancy and APOBEC1
target regions (not shown), and that in principle, the change in a single nucleotide within
the miRNA-binding site has the ability to modify miRNA binding (Figure 3.2.2). This
agrees with what has been found for ADAR edited miRNAs49,104. This is significant
because editing of miRNAs results in stringent and tissue-specific gene regulation, which
is crucial for development. By editing miRNA target sites, a shift or redirection of target
genes could be created, given that the pool of miRNA increases. This is yet to be
investigated for both Apobec1 and ADAR editing. Further discussion on miRNA
detection and regulation is presented on chapter 7.3.
During the course of my work, Davidson’s group at the University of Washington
also examined the transcripts of liver and intestine of wildtype and Apobec1-/- mice, and
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observed that in those systems, editing also results in altered protein expression105. His
group conducted differential gene expression analysis, and in contrast to my data, he
found that a few hundred genes were differentially expressed between wildtype and
Apobec1-/- enterocytes. Among those, 17 edited genes were differentially expressed.
Furthermore, using SILAC (method discussed in section 3.3) they were able to find 26
edited genes differentially translated with a magnitude of two fold changes. This agrees
with what I have reported in figures 3.3.1 and 3.3.2A, and points to a conserved function
of Apobec1. They also showed differences in expression of CD36, which agrees with my
findings, presented on figure 3.3.1B. However, when I analyzed translation globally via
ribo-seq (method discussed in section 3.3) I didn’t observe significant differences
between the wildtype and Apobec1-/- genotypes. This could be an inherent difference
between the two systems: enterocytes vs. macrophages. Alternatively, it could be that the
changes in protein expression I observe in Cd36, for example, are result of an alternative
mechanism, such as ribosome stalling. Caveats on ribo-seq method are further discussed
on section 6.3, below. Blanc and collaborators, however, did not explore further the
implication of the observed protein changes in enterocyte biology.
Altogether, changes in protein expression have implications for the fine-tuning of
macrophage responses to changing environments. Previous investigations of the
functional consequences of RNA editing have focused on instances where transcripts are
edited with very high frequency and/or alter decoding by targeting genic sequences,
which makes them have clear biological implications (e.g. APOBEC1 editing of
Apolipoprotein B58 and ADAR editing of GluR96,97). However, the collective functional
consequence of targeting a large number of transcripts has never been examined, and is a
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long standing question in the field. One of the challenges of such an analysis is the low
frequency of editing in the vast majority of sites. Altogether the frequency of APOBEC1
editing and the resulting changes in protein expression we have found in BMDMs are
modest. We hypothesized that these small changes would not be sufficient to have
biological consequences by themselves. However, it is possible that the sum of small
changes in a certain pathway or function would make an important contribution to the
resulting activity.
Indeed, when I looked closely at two of the most important activities of
macrophages, migration and phagocytosis, I discovered that cells from the two
phenotypes are indeed not equivalent (figure 5.1). In the case of phagocytosis, I found
that editing targets several structural proteins that are essential for the formation of the
mature lysosome, as well as proteins involved in the formation of proton pumps, also
necessary for the acidification of the phagosome. Furthermore, some other proteins,
which were not specifically identified to be in the same pathway through literature
mining, but are nevertheless necessary for uptake of particles, such as cytoskeleton
remodeling proteins and a scavenger receptor, are also edited.
Neither of the above mentioned proteins would represent a good candidate for
further studies on their own due to the low fraction of edited transcripts at the population
level. Therefore, new strategies would need to be devised in order to dissect the exact
contribution of each one of them to the overall phenotype. This may involve examination
at the single cell level, where I demonstrate variability in terms of editing exists among
cells of the same genotype (in figures 4.2.3 and 4.3.1). In such a scenario, a target that is
edited at a low frequency in the population could be highly edited in just a subset of cells,
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in which the consequences of editing would be magnified. For example, let’s take the
case of migration, where Apobec1-/- macrophages seem to be unfit to migrate whereas
their wildtype counterparts do so quite efficiently (figure 5.1): if we were to look at a
subset of macrophages that migrate more efficiently and therefore cross the membrane
first, we might find that they posses a particular editing signature that is different from
the macrophages that migrate at a slower pace. This kind of study would be relevant
because low frequency editing is actually quite pervasive, especially in the case of ADAR
editing, and insights from this work may be applicable to other scenarios, such as the
brain. Additionally, given that other epitranscriptomic marks have such a dynamic nature,
I expect that the study of the sum of editing events, C to U as well as A to I, will uncover
a wonderfully complex regulatory network.
Furthermore, macrophages have the characteristic that they are very plastic, that
is, they are able to change their phenotype in response to varying environmental cues.
Here, I provide two key findings that have implications in macrophage plasticity and may
contribute to heterogeneity in cells that appear identical (as defined by gene expression
measurements): (1) Editing is variable between cells from a seemingly homogeneous
population (as shown in figures 4.2.3 and 4.3.1), and (2) Apobec1-/- monocyte
differentiation is altered in the absence of editing (as shown in figure 5.2.2). These results
indicate that perhaps editing is involved in the formation of subsets of cells with different
capabilities, some of which are perhaps better equipped for specific environments and
may act as “first responders” that eventually signal to the rest of the population in order
to create a coordinated response. This possibility needs further investigation but it is a
very enticing hypothesis.
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Altogether these results predict alterations in the monocyte population in
Apobec1-deficient mice that might result in physiological alterations in the mice. Indeed
this is the case in brains of aged mice, where our collaborators found alterations in the
distribution of microglia, accompanied with inflammation (which under normal
conditions is absent in the brain). Even though I did not provide direct evidence that
editing is involved in creating this phenotype, I do believe that there is a connection. If
editing is indeed creating subpopulations of cells that have “special” characteristics, such
a subset in the context of the brain may be playing a modulating role, in charge to
maintain homeostasis, preventing unnecessary inflammation. A finer characterization of
the heterogeneity of microglia within the cell would be necessary to test for this
hypothesis and conditional deletion of APOBEC1 within this subpopulation would be
necessary in order to directly link editing to the phenotypes observed.
However, the consequences of APOBEC1 deficiency in the brain do affect the
mice significantly. Further research from our collaborators at Dr. Bulloch’s lab found that
these physiological changes are accompanied by alterations in mouse behavior (personal
communication), which highlights the importance of APOBEC1 in modulating
homeostasis. The work of our collaborators is likely to be key in recognizing
physiological alterations in the Apobec1-/- mice, and in establishing a link between
APOBEC1 editing and brain disorders.

6.2. Caveats on the molecular characterization at the RNA level
At a first glance we may conclude, upon examination at the molecular level, that
the function of APOBEC1 can be attributed to the modulation at the protein level, and
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that the transcripts affected undergo no alternative fates than their unedited counterparts.
That is, edited and unedited transcripts are equivalent to the cell. However, Davidson and
collaborators have reported differential expression between the two genotypes in
intestine, which also leads to differential translation of edited transcripts105. This
discrepancy may be a reflection of the different cell systems used: enterocytes vs.
macrophages. But the possibility still exists that true differences are being obscured due
to the fact that Apobec1 does not edit with 100% efficiency at every site. Therefore, the
currently available genome-wide comparison is of a true editing deficient (Apobec1-/-) to
an almost deficient (wildtype) counterpart. This is indeed one of the major obstacles with
the gene expression, stability and localization measurements and in general, to the
complete molecular characterization of edited transcripts.
Such characterization is possible, using for example the constructs like the ones
employed here for luciferase assays. However, this kind of assay would be cumbersome
and low throughput. A better approach would entail the analysis of both edited and
unedited transcripts within the wildtype sample. Such an experiment would have the
added advantage that both transcripts are subjected to the same milieu and have as similar
availability to the same RNA binding proteins as possible. Current technology does not
allow for such an experiment. However, one of the ways in which I envision one could
tackle this problem is through selective tagging of edited transcripts either via
complementation with fluorescent probes, or alternatively, by engineering an APOBEC1
enzyme that is fused to a protein that adds an additional tag (e.g. a methyl mark) to
APOBEC1 bound (and thus presumably edited) transcripts. Such marked transcripts
could then be separated and quantified (at different time points for stability or in the
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different fractions) or sequenced independently from the untagged (and presumably
unedited) ones (Figure 6.2, below).
A second option is to engineer an APOBEC1 enzyme that is capable of editing
each transcript 100%, which would be informative for fine molecular characterization of
transcript expression differences and protein production. However, it would not allow us
to see what biological consequences are truly the results of fine-tuning. Moreover, it
would eliminate the cell diversity created by hyperediting, which in its complexity may
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Figure 6.2 | Proposed methodology to follow edited and unedited transcripts
within the wildtype sample. (A) A modified Apobec1-tagging protein fusion will
both edit and tag transcripts during transcription. Cells that express this fusion
protein can also be treated with Actinomycin D for stability measurements or any
other substance of interest, for example, LPS. (B) RNA from those cells can be
retrieved and edited transcripts separated from the pool via any method that is
best for selecting the specific tag on the RNA (e.g. immunoprecipitation (IP),
column separation, etc.). Once the fractions have been separated, gene expression
analysis can be performed.
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be the core of APOBEC1 editing, whatever that may be. The main caveat of engineering
a protein that has 100% efficiency is that it could have off target effects, such as DNA
editing. It has been reported that Apobec1 (especially of rat origin) can induce DNA
mutations and promote cancer106,107. In a study by Severi and colleagues, rat Apobec1 was
shown to target a GFP reporter inserted into DT40 chicken cells107, which inactivates
expression of GFP, a system used to extensively analyze AID-mediated DNA editing108.
They found that the mutational signature of APOBEC1 resembles that of AID.
Furthermore, they demonstrated that a similar process happens in K562 human cells (a
model of chronic myeloid leukemia), whose mutational sequence context resembles that
of esophageal adenocarcinomas. This shows that off target effects can be related to the
level of expression of Apobec1. It has been proposed that the limiting factor preventing
high amounts of APOBEC1-mediated ApoB editing is the amount of ACF, which acts as
a repressor of Apobec1. This could also be the case of overexpression of Apobec1
leading to DNA methylation, albeit not necessarily through ACF.
One possibility that could be examined is whether APOBEC1 contributes itself to
the stability of transcripts. It has been previously reported that APOBEC1 has affinity for
AU rich sites that have been shown to be present in several untranslated regions of
transcripts which are known to undergo fast degradation70. Upon APOBEC1 binding, the
half-life of such transcripts apparently increases. Given that the transcripts affected by
APOBEC1 in macrophages are also AU rich, the possibility that APOBEC1 itself and not
only the editing is responsible for the long half-life still remains to be examined. In order
to test for this, Apobec1 conditional mutants would need to be constructed. One of the
main obstacles for this is the lack of knowledge of the crucial residues necessary for
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editing. A report by MacGinnie et. al. identified several residues responsible for Apobec1
editing of ApoB through mutational analysis. They found that a histidine to arginine
(H61R) yielded a catalytically dead enzyme and glutamic acid to glycine (E63G) resulted
in binding but not editing of ApoB mRNA in vitro109. However, when we tested whether
these mutations would eliminate editing of Apobec1 targets in macrophage, we found
that both mutations resulted in editing.

6.3. Caveats on the molecular characterization at the protein level
The extent to which protein regulation by APOBEC1 editing is the result of
miRNA binding still needs to be further investigated. We identified 19 transcripts in
which there were sites that could be created or destroyed, but there were further miRNA
binding sites contained within the footprints that were seemingly unaffected. However,
we estimate that a larger number of binding sites may be targeted in the cases where
hyperediting is pervasive. In these cases, the complexity of the possible combinations
makes it difficult to estimate the specific contribution of editing at any site, including
sites relevant to microRNA regulation.
The binding of Argonaute and mature mRNA-miRNA complexes leads to their
interaction with the RISC complex, which in turn leads to gene inhibition via three main
mechanisms: site-specific cleavage, mRNA degradation and translational inhibition. Both
site-specific cleavage and mRNA degradation would result in differences, albeit small, in
gene expression110,111. The latter of the processes occurs commonly in mammals and is
established when the decrease in protein production is greater than the reduction in the
corresponding mRNA levels112. Given that we have not been able to observe differences
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in gene expression or stability in transcripts derived from wildtype vs. Apobec1-/-, we
speculate that the process editing is involved is in translational repression.

The

mechanism for this type of repression is not yet fully understood, but several models have
been proposed to induce repression at several different stages of translation, including
initiation113–117,

increased

premature

termination118

and

impaired

elongation112.

Furthermore, it has been reported that Ago2 binds directly to the m7G-cap of the mRNA
preventing translation initiation119. We speculate that any of these mechanisms is
responsible for the miRNA regulation. However, the analysis of whether any one or
several of these mechanisms is involved in the APOBEC1-mediated protein regulation is
still to be investigated.
Given that the vast majority of edited transcripts are not predicted to contain a
miRNA binding site or have one created or destroyed by editing, we decided to consider
whether regulation was also possible for these transcripts. We observed through
luciferase assays, where the 3’UTRs of edited transcripts were fused to the luciferase
reporter, that miRNA independent regulation is also possible. Interestingly, this is also
the case for a subset of transcripts, most notably the ones that are hyperedited. A finer
dissection of which site or sites are the most important for this regulation is still to be
performed. Additionally, it does appear that a higher frequency of hyperediting correlates
with higher protein repression. However, in the case of the hyperedited transcripts B2m
and Lamp1, we were unable to see differences in endogenous protein levels. We
speculate that if only a subset of edited transcripts is responsible for the repression of
protein, it could get lost in the bulk analysis. This underscores the importance of analysis
of single cells, which would be able to show whether for a subset of cells that are
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enriched for a certain type of hyperedited transcripts, we would be able to see differences
in the endogenous expression of such proteins. We believe this might be the case because
we also found a special example (CD36) where the regulation shown in the luciferase
assays is also present in the endogenous protein levels.
Differential ribosomal binding of a subset of Apobec1 edited transcripts was
recently reported105, corroborating my luciferase results (Figure 3.3.1). However, when
we looked globally at the translational output through sequencing of the polyribosomebound fraction, we observed only subtle differences between the translation of edited
genes between wildtype and Apobec1-/-. This is not completely unexpected because thus
far, we have not observed big changes except for the case of CD36.
Some of the caveats of Ribo-seq are that it is unable to distinguish stalled
ribosomes or for transcripts that are translated with higher or lower efficiency, or those
which are stalled120,121, due to its lack of temporal information. For example, there are
higher amounts of native CD36 protein in Apobec1-/- BMDMs, but its transcript is not
one of the highest differentially ribosome-bound. It is possible that this transcript is one
such example of an efficiently translated transcript. Given that the differences we observe
are subtle, a temporal analysis would be helpful to determine whether editing has a role in
either stalling or translation efficiency. The latter is a process that is highly dependent on
the 3’UTR length122 and binding factors123–125, whose interaction with the 3’UTR could be
inhibited by editing.
Furthermore, Apobec1 editing events cannot be observed in the ribosome
footprints, as the footprints only cover the coding region of transcripts and editing events
are almost exclusively located in the 3’UTR. In order to test whether edited transcripts
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are equally able to bind ribosomes, the proportion of edited transcripts in total vs.
ribosome-bound RNA should be quantified. In order to do this, I devised an experiment
involving an alternative ribosome capture technology, called translating ribosome affinity
purification (TRAP)-seq126. TRAP-seq takes advantage of Ribosomes tagged with a GFP
tag for purification of the ribosome bound fraction. In the published method, the RNA is
collected and ribosomes are immunoprecipitated using GFP-specific antibodies and
stringently washed. After ribosome pool down, the entire transcripts are available and
library preparation for direct RNA sequencing of both fractions is possible. For the
detection of editing, I propose to perform amplicon sequencing of the RNA in both the
pool down tagged ribosome and whole RNA fractions, using a similar method as
described in section 4.3, which uses molecular tagging of transcripts (see figure 6.3.1
below). I believe this method would give a unique insight into the mechanism by which
edited transcripts are translated, that could explain the luciferase results presented in
Figure 3.3.1 (see figure 6.3.2 below).

6.4. Steady state versus activated macrophages
This work provides an overview of the possible functions of APOBEC1 in
macrophage biology. However, these studies are a mix of steady state and activated
macrophages. I characterized the edited sites in steady state BMDMs, and showed that
these cells gave rise to altered phagocytosis and migration; and I showed that Apobec1
could get induced after LPS stimulation. Therefore, it is important moving forward to
characterize how editing is altered during the activation of cells, which could give insight
into Apobec1 function during an inflammatory response and would clue us into which
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Figure 6.3.1 | Modified TRAP-seq method to identify ribosome-bound edited
transcripts. Depicted are the possible method for detecting editing within
ribosome-bound transcripts. Using GFP tagged ribosomes, the fraction of RNA
being translated can be isolated from the untranslated part. Reverse transcription
with barcoded primers can help identify individual RNA molecules after PCR
amplification. Finally, the PCR amplicons can be used for library preparation and
high throughput sequencing.
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Figure 6.3.2 | Scenarios that would explain differences in protein expression.
Depicted are the possible explanations that would result in the differences
between wildtype and Apobec1-/- genotypes shown via luciferase, from looking
at the different scenarios of ribosome binding.
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aspect of inflammation is being involved, given that the experiments currently available
are inconclusive (figure 5.3).
On the other hand, we unexpectedly encountered that APOBEC1 may play a role
in monocyte differentiation. Macrophages are a heterogeneous population of cells that
have, for research purposes, been classified into different categories given their activation
and differentiation states. Even though BMDMs are an excellent model for the study of
macrophage responses, they do not represent the functional state of most monocyte
populations in vivo. The closest relatives of BMDMs in vivo are fully differentiated
tissue-resident macrophages. Therefore, many of the observations from the in vitro
studies may or may not apply to these populations. Edited sites within the MDP, cMOP
and Ly6+ and – populations remain to be determined. These could shed some light into
the role of Apobec1 in the differentiation and also, into which compensatory mechanisms
are in place for normal development vs. ones that have developed after grafting.
It is important to consider also that the cells derived from grafting develop in an
inflammatory environment that is the result of whole body irradiation. It is possible that
the two environments are not equivalent and that Apobec1 only plays a crucial role when
cells are exposed to certain inflammatory environments. If this were the case, it would be
relevant for the observations in aged brains, where there is an established inflammatory
environment. It would also help shed light on the mechanism by which the phenotype of
clustered microglia and inflammation in Apobec1-/- aged brains arises: activated
microglia provided a pro-inflammatory environment that results in degradation of
neurons; or inflammation from some other origin activates otherwise normal microglia
and initiated the brain alterations. If inflammation leads to Apobec1 expression (as shown
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in figure 5.3) and Apobec1 is involved in the regulation of monocytic cells under
inflammatory conditions (as shown in figure 5.2.2), it is possible that the underlying
mechanism of Apobec1 is the regulation (through editing or indirectly) of genes that
maintain the monocyte program. This could be a potential mechanism underlying the
aberrant activation of microglia in the brain of Apobec1-deficient mice: they lack
adaptability to the inflammatory environment due to APOBEC1 loss.

6.5 Closing remarks
The substantial phenotypic diversity of monocytes is established epigenetically,
and maintained by local environmental cues. Hence, discrete monocyte subsets have
unique transcriptomic signatures. However, phenotypic heterogeneity is also present
within specific subsets with identical transcriptomic signatures. Here, I demonstrate that
APOBEC1-mediated RNA editing generates sequence heterogeneity in macrophages that
appear identical by gene expression measures, but which nevertheless can show
phenotypic differences.
These epitranscriptomic sequence changes occur mostly in transcript 3'
untranslated regions (UTRs) and result in alterations in the quantity of individual proteins
through a variety of mechanisms, including miRNA target sequence ablation. The data
presented here constitutes the first instance where RNA editing of clusters of transcripts
that aggregate in common pathways is shown to specifically affect the output of those
pathways, and by extension, cell physiology.
My work suggests that the sequence diversity contributed by RNA editing might
provide subsets of cells with distinct informational content. Further, our work implies that
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RNA editing might underlie or anticipate the functional heterogeneity apparent in
populations of cells of monocytes, the mechanism for which is currently not understood.
The data also suggests that editing may contribute to the substantial phenotypic diversity
of monocytes, such that phenotypic heterogeneity is also present within specific subsets
with identical transcriptomic signatures.
I also demonstrate that changes in protein abundance initiated by RNA editing
have functional consequences for the physiology of the monocytes, both in vitro and in
vivo, predicting that slight differences in the maintenance of monocyte subsets might,
over time, have critical consequences for the health of the organism.
Given that standard genome-wide association studies (which catalog DNA
changes) have not been particularly successful in predicting disease progression or
manifestations of neurodegenerative or psychiatric disorders, the development of a link
between aberrant RNA editing and brain disorders, might be useful for identifying
signatures, shared with peripheral monocytes, that can be used in diagnosis, prevention or
treatment.

89

CHAPTER 7. METHODS

7.1. Mice and isolation of BMDMs
C57BL6 littermate or age-matched mice were used at 6-12 weeks of age.
Apobec1-/- mice were a gift from N.O. Davidson (Washington University School of
Medicine). Mouse femurs were removed and flushed with cold PBS onto a cell strainer.
Precursor cells were plated onto untreated 10cm dishes and incubated in a humidified
37°C, 5% CO2 incubator for 7 days in DMEM, 10% FBS 1% Non-essential amino acids
(Invitrogen), 0.1% BME, 20ng/mL M-CSF (Peprotech), replacing half of the media (with
complete media plus 40ng/mL M-CSF) every 3 days. Macrophage surface markers:
F4/80 (Invitrogen) and Cd11b (BD biosciences) were confirmed via flow cytometry on a
FACS Calibur flow cytometer after the 7-day maturation.

7.2. mRNA-Seq
RNA was extracted from macrophage cultures using the Ribopure kit (Ambien).
DNAse treatment was performed with Turbo DNAse (Ambien). mRNA libraries for
Illumina sequencing were prepared as previously described82 with the following
modifications: 1) polyA selection was performed with Sera Mag oligo-dT magnetic beads
(Thermo) 2) mRNA fragmentation in fragmentation buffer was adjusted for higher read
length, and was performed for exactly 4 min 45s 3) After double-stranded cDNA libraries
were separated by agarose gel electrophoresis and fragments ranging from 275-325nt
were excised. Single-end 75nt sequencing was performed on Illumina Genome Analyzer
IIx (GAIIx) yielding 28-33 million reads. Trimmed reads were mapped to the C57LBL/6
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mouse reference genome (NCBI37/mm9) using Tophat (v1.3.3) and Bowtie (v0.12.8)
with the tophat parameters “--solexa1.3-quals -g 1 --coverage-search.” Gene expression
levels were calculated using Cufflinks (v1.2.1) using the Ensembl gene set.

7.3. RNA editing detection pipeline
A vector consisting of the number of A’s, T’s, G’s and C’s that occurred at each
coordinate were constructed from the SAMtools pileup33 for both the wildtype and
Apobec1-/- bulk

RNA-seq

alignments

that

were

de-duplicated

using

Picard

(http://broadinstitute.github.io/picard). For each coordinate that exhibited a C-to-T
change only in the wildtype sample (that is, not in the knockout alignment, such that only
APOBEC1-dependent C-to-T changes are kept) and met a number of stringent quality
control thresholds (minimum of five reads covering site, with at least two reads
supporting the editing event, excluding sites that showed multiple types of transitions;
and discarding reads that contain indels, support an edit in the first or last two base pairs
of a read), the angle between the corresponding vectors for the wildtype and Apobec1-/were compared. Putative hits were retained if the magnitude of the wildtype vector was at
least 15 and the angle between the wildtype and Apobec1-/- vectors was at least 0.11
radians (approximately equivalent to a minimum coverage of 20 reads and an editing rate
of 10%). Potential sites were also filtered against genomic DNA-derived SNPs
indbSNP138, and removed if they occurred within four base pairs of a splice junction
(using the exon junctions compiled by the Zhang lab, using OLego34) or in simple or
tandem repeats (softmasked regions by RepeatMasker). Reads supporting edits were run
through BLAT35 to ensure that they were not ambiguously mapped. The pipeline was
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programmed using Bash and Python with the Pysam (https://github.com/pysamdevelopers/pysam) pileup engine. RNA editing events were then validated by designing
primers proximal to the sites of interest, amplifying those regions from cDNA and
genomic DNA from both wildtype and Apobec1-/- cells, and performing colony
sequencing.

7.4. Subcellular fractionation
A total of 10x106 bone marrow derived macrophages were resuspended in
200μL of cold cytoplasmic buffer (0.15% NP-40, 10mM Tris pH 7.5 and150mM NaCl)
and incubated on ice 5 minutes, in order to break the cell membrane. The nuclei were
separated by centrifugation at 16,000 rcf, 10 minutes at 4ºC. The cytoplasmic supernatant
was separated and the nuclei pellet was washed twice with cold PBS. The nuclei were
gently resuspended in 100μL of glycerol buffer (20 mM Tris pH 8, 75 mM NaCl, 0.5 mM
EDTA and 50% Glycerol). Next, 100μl of nuclei lysis buffer (20 mM HEPES pH7.6, 7.5
mM MgCl2, 0.2 mM EDTA, 0.3M NaCl, 1M Urea, 1% NP40) were added and lysed by
vortexing twice for 2 seconds and incubating 2 minutes at 4C. The chromatin fraction
was separated with a spin at maximum speed, 2 minutes at 4C. Total RNA was separated
from both the nuclear and cytoplasmic fractions using phenol chloroform isoamyl alcohol
extraction. The fractionation efficiency was determined by western blot using alpha
tubulin (Sigma 4500088) and H3K27Me3 antibodies (Abcam 6002).
RNA half-life estimates after exposure to actinomycin-D.
Cultures of BMDM were exposed to actinomycin-D at a concentration of
10μg/mL for periods of 0, 0.5, 1, 2 and 5 hours. RNA was collected via Trizol and
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reverse transcribed using Superscript III and polydT primers. The concentration of edited
genes Cybb, Sptssa, App, Cd36, Lamp1, Lamp2 and B2m was determined by RT-PCR,
normalizing to GAPDH. Additionally, the genes Atp5a1 and Jun were measured by RTPCR as controls for long and short-lived transcripts in macrophages, respectively. The
half-life of the transcripts was calculated using the formula t1/2= ln(2)/kdecay, where kdecay is
the slope of a semilogarithmic plot of the concentration of mRNA in time.

7.5. HITS-CLIP analysis
Argonaute HITS-CLIP was performed in conjunction with the Darnell lab as
previously described84, with a few modifications: BMDMs were isolated from 3 wildtype
and Apobec1-/- littermate pairs. BMDMs were matured as described above and
crosslinked 3x at 200mJ/cm2 in 3mL of 1xPBS on a bed of ice. BMDMs were scrapped
off the plates, flash-frozen and stored at -80C. Frozen cells were thawed and lysed in
1mL PXL lysis buffer (1x PBS, 0.1% SDS, 0.5% Na-DOC, 0.5% NP-40) with complete
protease inhibitor. Cells were DNAse treated with RQ1 RNAse-free DNAse (Promega).
RNAse treatment performed with high (1:100) or low (1:10,000) RNAse A solutions.
Protein A beads (first loaded with rabbit anti-mouse IgG bridging antibody (Jackson
ImmunoResearch, at 2.3 mg/mL)) were then incubated with 3 uL Ago antibody (2A8
ascites provided by Dr. Z. Mourelatos) per 400 uL of beads and rotated for 3 hours at
4°C. Lysates were incubated with primary antibody-loaded beads for 2 hours at 4°C and
washed in a series of high- and low- stringency washes, after which 5'phosphate
dephosphorylation was performed, and a radiolabeled linker was ligated to the 3'end of
the bound RNA species. Cold L32 RNA linker with 5’ phosphate was added to this
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mixture after 1 hr and it was incubated overnight and washed 3x with PNK buffer. 5’
ends were re-phosphorylated with T4 PNK. Protein:RNA complexes were eluted off the
beads in NuPAGE loading buffer (Invitrogen) and supernatants were run on Novex
NuPAGE 8% Bis-Tris gels (Invitrogen) in MOPS running buffer (Invitrogen), transferred
onto Protran BA85 nitrocellulose (Whatman) and exposed to Biomax MR film (Kodak).
Regions that corresponded to Ago:mRNA and Ago:miRNA complexes were
excised from the membrane and treated with proteinase K (4mg/mL Roche). RNA was
then extracted via phenol-chloroform extraction and ethanol precipitation. 5’ linkers with
a degenerate nucleotide end were ligated to the extracted RNA with T4 RNA ligase
(Fermentas). The ligated reaction was then subjected to DNAse treatment with RQ1
DNAse (Promega) and extracted with phenol-chloroform and ethanol precipitation,
reverse transcribed with Superscript III (Invitrogen) and PCR amplified with Accuprime
Pfx Supermix (Invitrogen) for 20-35 cycles. PCR products were run on a 10% denaturing
polacrylamide gel and visualized with SYBR Gold (Molecular Probes). Products running
between 60-100nt were excised from the lowest cycle number with visual product and gel
extracted. Additional PCR amplification followed by gel extraction was performed with
fusion primers as previously described to provide the platform for Illumina sequencing.
10-30uL of 10nM DNA was submitted for sequencing on Illumina HiSeq.
Processing and alignment of HITS-CLIP reads
HITS-CLIP reads were filtered by quality (the first 5 nucleotides had a minimum
quality score of 15 and the next 45 had a minimum mean score of 15) and exact
sequences were collapsed. The 5’linker was stripped off and Illumina adapter sequences
were clipped from the 3’ end (Fastx Toolkit). Reads were then parsed by size into mRNA
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(≥25nt) and miRNA(≥17nt and ≤ 24nt) fractions. miRNA reads were aligned to mm9
using bowtie (v0.12.8) with the following specifications: “-l 17 -v 2 --best --strata -m
12”. To determine the best alignment strategy for his highly duplicated dataset we
determined that the mmu-miRNAs mapped to a maximum of 12 separate genomic
positions, so therefore we allowed up to 12 alignments per read. Read counts were
quantified in SeqMonk (http://www.bioinformatics.babraham.ac.uk/projects/seqmonk/)
using miRNA intervals defined by miRBase (v18). miRNAs mapping to multiple
positions in the genome were then collapsed.
mRNA reads were uniquely aligned to mm9 using bowtie (v0.12.8) with the following
options: “-v 2 --best --strata -m 1”. A second step of PCR duplicate removal was
performed as previously described (9) in which reads with the same 5’ 5nt degenerate
linker and the same coordinates were removed. This step eliminates true PCR duplicates,
in which sequencing errors were also introduced, and would therefore be missed by an
exact sequence collapser. Clusters made up of ≥8 reads and a 5nt overhang were
identified. The peaks of the clusters were identified as previously described (8) and the
“Ago footprint” around the cluster broadly defined as the region 32nt upstream and 30nt
downstream from the peak or narrowly defined as the region 22nt upstream and 24nt
downstream of the edited say (region in which Ago is bound 100% of the time). The read
depth of each footprint from HITS-CLIP and RNA-Seq was calculated using Seqmonk
and CLIP depth was normalized to transcript expression (RNA-Seq read depth) to define
the “Ago occupancy” (reads per million mapped CLIP/reads per million mapped RNASeq). We find this method to be an accurate normalization, as it takes into account
regions within each transcript that could be differentially expressed or differentially
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mapped, a phenomenon neglected when normalizing to total transcript expression. Ago
footprints were filtered to 17,477 that were contained within “expressed” regions, defined
as an RPM of greater than or equal to 1, as this provided reasonable coverage of these
regions, and would eliminate the any problems with artificially increasing Ago footprint
occupancy values by normalizing to a value less than 1. The biological complexity (the
number of replicates contributing to each Ago Footprint) was calculated based on the
replicate contributing ≥2 reads to the footprint. “High-confidence” footprints (14,781)
were defined as having a biological complexity of ≥2. As all APOBEC1 editing and most
miRNA targeting happening within the 3′UTR of a given transcript, we narrowed our
search to only 3′UTRs. We generated a permissive 3′UTR database from RefSeq by
merging (with Bedtools) overlapping 3′UTR regions, thereby defining a region as a
3′UTR if it was catalogued as such in any transcript isoform. 6,270 “high-confidence”
footprints were contained within these merged 3′UTRs. Ago footprints were then
overlapped with APOBEC1 editing events to identify regions of potential
Ago:APOBEC1 interaction.
miRNA target search
After the identification of high-confidence Ago footprints, we performed an
exhaustive search to assign miRNA targets to those footprints and identify regions where
APOBEC1 editing could create or destroy a miRNA target region. Using miRNA
alignment data, we generated a list of bound miRNAs, defined as those that had a
biological complexity of 3 in one of the two genotypes. Using a custom python script
(available upon request) we scanned the footprint sequences for “canonical” matched
miRNA 6mer seed regions (positions 2-7 of the mature miRNA sequence), as well as
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other non-canonical matched 6mers from the 5’ end of the mature sequence (positions 16 or 3-8). We also scanned the footprint sequences for “fuzzy” 6mers and 7mers (1
nucleotide mismatch) and G-bulge seed regions (1 G insertion). Footprints were analyzed
for the “best” miRNA target region fit, based on the sequence proximity to the footprint
peak and the amount of the miRNA bound to Ago. We identified a number of target
regions that were either created or destroyed by APOBEC1 editing events and tested
these with standard luciferase reporter assays (described below).

7.6. Luciferase Assays
For miRNA dependent analysis: site-specific mutagenesis was performed on
unedited (matched reference sequence) version target 3′UTRs and these were cloned into
luciferase vectors. Renilla luciferase served as an internal control. HEK293T cells were
transfected with edited or unedited constructs plus the miRNAs of interest (synthesized
by Dharmacon) using the DuoFECT reagent (and according to the manufacturer’s
recommendations) or an unrelated microRNA control. Cells were returned to the
incubator for 48 hours after which luciferase expression was assessed. Cells were lysed
with passive lysis buffer by shaking at RT for 15min and subjected to one freeze-thaw
cycle at -80°C. Firefly (experimental) and renilla (transfection control) luciferase
expression were measured using the Dual-Luciferase reporter system (Promega) and a
Fluostar Omega plate reader. Background luciferase levels (pmaxGFP) were subtracted
from experimental samples. Firefly expression was normalized to Renilla (transfection
control) for each construct. We calculated the percentage of repression for both edited
and unedited constructs using the reduction in luciferase activity induced by
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overexpression of the microRNA of interest relative to the expression of the unrelated
microRNA control (following the methods used by Loeb et al.127). The statistical
significance for the differences was determined using a student’s T test with α= 0.05
(Prism). The mRNA-miRNA pairs tested were Sptssa with miR17 (miR501 was used as
unrelated control), Rac1 with miR669 (miR17 as control).
For miRNA independent analysis: a series of edited and unedited 3′UTRs were
cloned using a high fidelity polymerase (Turbo, Invitrogen) from wildtype (“edited”) and
Apobec1-/- (“unedited”) macrophage cDNA into a subclone vector (Strataclone). Clones
were screened and representative clones for each degree of editing (single-site, number of
hyper-edited events, etc.) were inserted downstream of a firefly luciferase in a dualluciferase vector (Promega).
Apobec1-/- BMDMs were transfected with luciferase constructs and pmaxGFP
transfection control vector using the Amaxa Mouse Macrophage Nucleofactor kit
(Lonza). Cells were returned to the incubator for 24 hours after which luciferase
expression was assessed. Cells were lysed and luciferase was determined as described in
the previous section. In all cases, significance for the difference between each “edited”
and “unedited” pair was calculated by a Mann-Whitney test (Prism). We tested a total of
6 single-site edited transcripts (Cd36, Tmem55a, Sptssa, Sep15, Anxa5 and Rac1) and
several combinations of editing in hyper-edited transcripts (B2m, App, Lamp1 and
Adam10).
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7.7. High-throughput Ribosome profiling
Ribosome profiling libraries were prepared using the Truseq Ribo Profile kit per
manufacturer’s instructions. Libraries were sequenced with 50 nt single end reads on the
Illumina HiSeq 2500. Alignment, and mRNA and RPF read counting were performed as
described in 20. Briefly, libraries were trimmed for adapters and quality using Trim
Galore. The resulting reads were initially aligned to mouse ribosomal RNA using bowtie
(v1.1.2). The remaining unmapped reads were then aligned to mm10 (using the reference
sequences and annotations provided by iGenomes (Illumina)) using Tophat2 (v.2.1.0) and
the following parameters: –bowtie1, –no- novel-juncs, –read-realign-edit-dist=0 (default
settings for the remaining parameters). mRNA reads were counted using HTseq in
intersection-strict mode, and RPF reads were counted using a custom script provided by
Xiao et al87. DESeq2 was then used to assess changes in translational efficiency (TE),
defined here as the ratio of RPF to mRNA reads, between the two genotypes. This was
achieved with the design ~ assay + genotype + assay:genotype + batch, and analysis run
as follows: dds <- DESeq(dds, test='LRT', full=design(dds), reduced = ~ assay +
genotype + batch), where assay indicates if the library was mRNA or RPF, genotype
indicates if the sample was WT or KO, and batch indicates the batch that the library was
prepared with. Differential gene expression analysis was also performed, with DESeq2,
using only the total mRNA reads generated from the Ribo-Seq experiment.

7.8. Single cell RNA-Seq
To generate single-cell libraries, wild-type bone marrow-derived macrophages
were flowed into a C1 IFC for mRNA seq (10–17 mm) chip using the Fluigidm system.
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Lysis, RT and PCR were performed using the SMARTer Kit designed for the C1
(Clontech, Mountain View, CA). The efficiency of chip loading (capture) was confirmed
by microscopy and any of the wells that contained either none or more than one cell were
noted and discarded from further library preparation and analysis. In all, 24 single cDNA
libraries were selected for library preparation on the basis of concentration and size
range, as determined via Agilent Bioanalyzer. Sequencing libraries were made from the
cDNA using the Nextera XT DNA Sample Preparation Kit (Illumina). To generate
conventional bulk RNA-seq libraries, total RNA was extracted using Trizol (Invitrogen,
Grand Island, NY) from 500,000 to 1,000,000 macrophages of each genotype (wild type
and APOBEC1_/_). A unit of 1 mg of the total RNA collected per condition was then
treated with DNase, and then processed using the NEBNext Ultra Directional RNA
Library Prep Kit for Illumina (NEB, Ipswich, MA).
Libraries were sequenced on the Illumina HiSeq 2000, generating 100-nucleotide,
single-end reads. Reads were trimmed for quality and adapters using Trim Galore!, and
then aligned to mm10 (using the reference sequences and annotations provided by
iGenomes (Illumina)) using Tophat2, allowing only unique alignments and up to 2
mismatches per 20-nucleotide segment. Gene expression was determined using
Cufflinks32. The correlation of gene expression between the ensemble of single cells and
the bulk was calculated using the Spearman and Pearson correlation coefficients.
Potential PCR duplicates were removed from single cell alignments using Picard
(http://broadinstitute.github.io/picard).
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7.9. Hierarchical Statistical Model
A lay summary of the method is described here; for full methods, including the
mathematical derivation, please see Harjanto el at. 201680. First, an editable site of
interest on a given RNA transcript and its associated probability of editing were selected.
The transcript can be modeled as a coin with a probability of falling on ‘Heads’ when
tossed equal to the associated editing probability (not necessarily 50%). We can think of
each single cell as consisting of a stack of coins (with each coin corresponding to the
same site on a different copy of the transcript), each having the same probability of
falling on ‘Heads’. Finally, we can think of the population of cells as a bag full of stacks
of coins, where the probability of ‘Heads’ for each stack is drawn from an unknown
distribution on [0, 1]. The variance of this distribution quantifies the diversity among
editing rates of different cells (or stacks of coins). The single-cell experiments correspond
to randomly picking any number of stacks from the bag and tossing some of their coins,
whereas the bulk experiment corresponds to randomly picking a large number of
individual coins from the bag, after emptying all the stacks in and mixing them together.
Because we assume that the edited sites can be treated independently, we can restrict
attention to just a single genomic location, for which we can estimate a posterior
distribution by applying Bayes’ rule and the appropriate Markov chain Monte Carlo
algorithms. The posterior density of the variance provides a quantification of RNA
editing variance.
To test the model, we performed simulations using artificial data sets comprising
of 20 cells exhibiting high levels of editing variance for a theoretical site, generated by
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randomly sampling the number of edited reads to attain effective editing rates only in the
region of 0-5% and 95-100%.

7.10. Targeted single-cell RT–PCR
To analyze editing of specific sites in single cells, single wild-type macrophages
were sorted into 96-well PCR plates with 5-ml of lysis buffer, containing 0.45% NP-40,
0.36Uml_1 RNAse Inhibitor and 0.18Uml_1 Superase-In (Ambion). RT–PCR
amplification was done with gene specific primers and the OneStep RT–PCR kit
(Qiagen), using a modified protocol. Single transcript molecules were tagged with
barcoded gene-specific primers that have an additional universal sequence, used in RT.
These primers were then digested with 1U of Exonuclease I (30 oC for 30 min; NEB).
Afterwards, a mix of universal forward and gene specific reverse primers were added to
the PCR mix and 35–40 cycles of PCR were performed. The PCR products were
introduced into bacteria using a TOPO TA cloning kit (Invitrogen) and single bacterial
colonies were sequenced using Sanger sequencing. The resulting sequences were then
aligned to the reference transcriptome (Macvector) and PCR duplicates were eliminated
using the barcodes.
Transcript specific primer sequences were as follows:
B2m primers:
RT:
50GGCCAGTGAATTGTAATACGACTCACTATAGGNNNNNNAAAGCAGAAGTAG
CCACAGGGTTG-30
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PCR-reverse: 50-TTAAGCATGCCAGTATGGCCGA-30
Anxa5 primers: RT:
50GGCCAGTGAATTGTAATACGACTCACTATAGGNNNNNNGTCGCCAATGTTTT
GGAT ACTACCATC-30
PCR-reverse: 50-GCGACACATCTGGAGACTATAA GAAGGC-30
Cybb primers: RT:
50GGCCAGTGAATTGTAATACGACTCACTATAGGNNNNNNGAGGGTTTGTGCCT
AGTCTTATTGCA-30
PCR-reverse: 50-GCATGCGCTCATCTTGTTTTGACTTC-30
Universal PCR-forward: 50-GGCCAGTGAATTGTAATACGACTCACTATAGG-30

7.11. Migration assay
BMDMs from wildtype or Apobec1-/- mice were starved in serum free DMEM,
containing 0.2% BSA and 20 ng/mL mCSF for twelve hours. The lower chambers of the
96 well chemotaxis plate (Neuroprobe 8um, cat. 106-8) were filled with 30uL of DMEM
0.2% BSA in the absence or presence of increasing concentrations of murine CXCL12
(Peprotech), in triplicate. Macrophage suspensions (in phenol red free DMEM (Life
Technologies) containing 0.2% BSA) were deposited on the top portion of the migration
plate and placed at 37°C, 5% CO2, for 4 hours. Cells that did not migrate were aspirated
off the top portion of the filter, which was also wiped with a cotton tip. BMDMs attached
to the lower surface of the filter were centrifuged in a 96 well black plate with clear
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bottom containing lysis buffer with CyQuant DNA-binding dye (Life Technologies).
Fluorescence (excitation 485nm- emission 530nm) was measured using the Synergy Neo
plate reader, after a 30-minute incubation at room temperature with gentle shaking. The
chemotactic index was calculated by dividing the fluorescence intensity of each sample
by the fluorescence intensity in the absence of chemokine. Data was analyzed using
Prism 6.0g software (GraphPad Software, San Diego, CA) and statistical significance of
the differences between the various conditions was determined using multiple measured
one-way analysis of variance, with Bonferroni’s correction for the t test.

7.12. pHrodo assays
Wildtype and Apobec1-/- BMDM were incubated with 1(MOI 10) or 10mL (MOI
100) of pHrodo Red E. coli BioParticles (Invitrogen) in HBSS at 37C without CO2 FOR
20 min. After the incubation period, cells were washed twice with HBSS and stained with
Alexa 488 F4/80. Cells were detached with 5mM EDTA in PBS and analyzed via flow
cytometry on a FACS Calibur flow cytometer.

7.13 Bone marrow chimeras
Bone marrow was collected from 8 Apobec1-/- CD45.2 and pooled; same with 8
wildtype CD45.1 mice. Lineage positive cells were depleted using a cocktail of MAC1,
GR-1, B220, CD4, CD8, CD3, Ter119, CD19, CD11c and NK1.1 biotinylated antibodies
(BD Pharmingen) together with streptavidin columns (MACS). Wildtype CD45.1 mice
(Jackson labs) or heterozygote for both CD45.1/CD45.1 and Apobec1+/- were lethally
irradiated (with two doses of radiation delivered 3 hr apart and totaling 950 rad) and
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injected (retro-orbitally) with a 1:1 mix of CD45.1 wildtype and CD45.2 Apobec1-/lineage depleted cells. Spleens from chimeric mice were collected 28 days post-transplant
in both backgrounds and 48 days in two mice transplanted in the CD45.1 background.
For the analysis of macrophages in spleen, cells were stained with Ax488 F4/80, PerCPCy5.5 CD11b, APC Ly6C, Aqua death cell exclusion, BV711 CD45.1, BUV395 CD45.2,
PE Ly6G, PE-Cy7 CD11c. For the analysis of bone marrow, cells were stained with
biotinylated CD3, CD19, NK1.1 and Ly6G; followed by staining with Ax488 CD115,
PE-CF594 Streptavidin, PE CD135, BV421 CD117, Aqua dead cell exclusion, BV711
CD45.1 and BUV395 CD45.2. T cells were identified as either CD3+CD4+ or
CD3+CD8+, with FITC CD4, PE CD3, APC CD8, Aqua dead cell exclusion, BV711
CD45.1 and BUV395 CD45.2. B cells in spleen were defined as CD19+B220+, stained
with Ax488 B220, PE CD19, Aqua dead cell exclusion, BV711 CD45.1 and BUV
CD45.2. In bone marrow, B cell progenitors were stained with Alexa 488 B220, PE
CD43, PE-Cy7 IgM, Aqua dead cell exclusion, BV711 CD45.1, BUV395 CD45.2. ProB cells were defined as IgM-B220+CD45high, Large Pre-B cells as IgMB220+CD43medFSC-Ahigh, and Pre-B cells as IgM-B220+CD43medFSC-Alow.

The

quantification of populations was done via flow cytometry using an LSR Fortessa (BD
Biosciences) cell analyser.

7.14. High throughput amplicon sequencing of edited fragments
CD11c+ and CD11Cneg cells were isolated from cortex and hippocampus by
MACS column separation. Briefly, cells were incubated with biotinylated CD11c
antibodies (BD) and the CD11c+ fraction was retained in a MACS (Miltenyi Biotec). The
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eluted cells were then incubated with a biotinylated CD11b antibody and the CD11c- (but
CD11b+) fraction was retained in a separate MACS column. A 300bp fragment
surrounding a predicted edited site was amplified from both CD11c+ and CD11c- cDNA
and genomic DNA. Next, all the PCR products were purified and mixed. Library
preparation was performed on the mixed sample using the Illumina True-seq kit and was
sequenced in an Illumina mi-Seq. Reads were aligned to the genome and editing
frequency was determined by counting the number of changes to the reference genome,
using a custom script.
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